+关注
飞哥非哥
医疗、电子、增强现实等方面的新产品研发
IP属地:广东
253
关注
131
粉丝
8
主题
0
勋章
主贴
热门
飞哥非哥
06-25 09:40
$兖矿能源(01171)$
咨询一下各位朋友,前阵子的分红大约多久可以达到港股通账号?
飞哥非哥
06-19
$Corner Growth Acquisition Corp 2(TRON)$
$SRM Entertainment, Inc.(SRM)$
前天就辟谣了,老川儿子不会在公司担任职务。
孙宇晨要上市了,特朗普小儿子将加入!这只股票隔夜暴涨647%
飞哥非哥
06-09
$特斯拉(TSLA)$
一个全球知名的、多方向的科技前沿企业,如果因为董事长跟总统吵了一架,公司(股价)就不行了,岂不是世界笑话?何况还是曾经帮过大忙的朋友。 民主党那些媒体、团体天天嘲笑、咒骂总统也没见受到什么伤害。
飞哥非哥
04-16
特朗普的目的是: 高端制造业会回流,比如半导体,中低端制造业全球重构,不再集中在中国,目前来看他可能会在一定程度上达到目的(大部分人看不懂老川,而且小看他)。 作为中国,通过几十年建设起来的制造业千万要想方设法保住,而且规模是面向全球的,产能巨大,从业人口众多,一旦失去要回来就很难了,所以对外贸问题一定要灵活处理,能屈能伸,否则会造成大量外贸企业的极度困难,涉及到几千万人的就业问题,而这几千万人口又会因家庭组合、消费等影响到更大的范围,很多反应都是连锁的,比如有的生产企业它内外贸都做,微利时代,一旦由于外贸砍掉一大块,企业就可能从盈利变成亏损,而亏损企业如果在一定的时间内看不到扭亏的可能性就可能会止损停业,这就不仅仅是影响外贸企业了。
飞哥非哥
02-22
缺乏核心竞争力
飞哥非哥
2024-12-18
$LQR House Inc.(YHC)$
是不是要被收购了?好像看到有一个12.20的投票截止日的邮件。
飞哥非哥
2024-11-23
这篇文章不错,转发给大家看看
抱歉,原内容已删除
飞哥非哥
2024-11-06
川普,马斯克必胜!智慧与正义!
飞哥非哥
2024-09-18
0.25% 大概率是25个基点
飞哥非哥
2024-09-06
稳定收益的股票
【华创交运*业绩点评】厦门国贸:1H24归母净利润8.4亿,主业短期承压,持续看好大宗供应链龙头转型广阔空间
飞哥非哥
2024-08-13
为人类健康努力
$IN8bio, Inc.(INAB)$
IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100
飞哥非哥
2024-06-08
$AppLovin Corporation(APP)$
现在到了收购
$Unity Software Inc.(U)$
最好的时机,再度出手吧!!一股换两股甚至2.5股,所有持有
$Unity Software Inc.(U)$
的人都愿意!
飞哥非哥
2024-03-18
$小i机器人(AIXI)$
马斯克开源人工智能大模型对AIxi是特大利好呀!!!刚好用于落地做应用市场,好好表现一下!
飞哥非哥
2023-12-21
分析的通透
抱歉,原内容已删除
飞哥非哥
2023-09-28
先讲个故事: 那个人太不像话了,以前每次碰到他都会给5个刀给我,从昨天开始居然说他也要向家人交代,以后每次只能给我2.5刀了!要是有给的更多的人,真不想碰到他了,有吗?居然还是他给的最多![捂脸]
$Unity Software Inc.(U)$
一个公司上市了就像一个人结婚了,从此有了对股东和家人的责任,年年花天酒地、入不敷出那是不行的,一个全球占最大份额的全平台游戏引擎股价从200多跌到20多,说明它原先够优秀够廉价,居然不准他为了盈利涨一点点价?何况涨价后还是最便宜的,骂他不跟用户充分沟通,那些大用户也没沟通翻脸不认人破口大骂就有理了?
抱歉,原内容已删除
飞哥非哥
2023-09-16
Replying to
@苹果拥护者
:
$Unity Software Inc.(U)$
通过硬件ID识别,即使你重新安装系统,服务器也能识别是否是重复安装,同理,欺诈性安装更能识别。如果同时记录几个硬件的ID,则即使你换了个别硬件也还能识别,比如硬盘序列号、网络物理序列号、CPU序列号等,这些都具备全球唯一性特征。//
@苹果拥护者
:1、所有休闲游戏都会和unity说拜拜 2、欺诈安装你如何识别?如何合作? 3、重复安装不同端口安装你又如何识别?这些都是无法识别的东西
@钛媒体APP:Unity回应:Runtime模式仅针对新安装游戏收取费用,90%以上客户不受影响
飞哥非哥
2023-08-10
利用好已经拥有的市场先发优势,抓住今年AI大爆发机会,未来可期!
飞哥非哥
2023-08-03
是的,现金收入那么多,净资产每股65美金,居然不分红,不然股价立马翻1-2倍。
@为而不争001:
$大全新能源(DQ)$
垃圾公司,不分红铁公鸡
飞哥非哥
2023-07-14
$诺基亚(NOK)$
反应有点过激了,预计的业绩也没下多少,几个点而已,只能说借机做空者厉害!
飞哥非哥
2023-07-01
躲过了美联储的围追堵截,却不小心中了港股的招!
@小虎活动:【有奖活动】一句话形容我的2023上半年
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3493163577009875","uuid":"3493163577009875","gmtCreate":1541635160644,"gmtModify":1576736880892,"name":"飞哥非哥","pinyin":"fgfgfeigefeige","introduction":"","introductionEn":"","signature":"医疗、电子、增强现实等方面的新产品研发","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":131,"headSize":253,"tweetSize":271,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":8,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":144,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.05.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.73%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.48%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":1,"location":"广东","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":9,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":449696198869584,"gmtCreate":1750815605788,"gmtModify":1750815607120,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01171\">$兖矿能源(01171)$ </a> 咨询一下各位朋友,前阵子的分红大约多久可以达到港股通账号?","listText":"<a href=\"https://laohu8.com/S/01171\">$兖矿能源(01171)$ </a> 咨询一下各位朋友,前阵子的分红大约多久可以达到港股通账号?","text":"$兖矿能源(01171)$ 咨询一下各位朋友,前阵子的分红大约多久可以达到港股通账号?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/449696198869584","isVote":1,"tweetType":1,"viewCount":107,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":447500306932040,"gmtCreate":1750291424975,"gmtModify":1750291426532,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TRON\">$Corner Growth Acquisition Corp 2(TRON)$ </a> <a href=\"https://laohu8.com/S/SRM\">$SRM Entertainment, Inc.(SRM)$ </a> 前天就辟谣了,老川儿子不会在公司担任职务。","listText":"<a href=\"https://laohu8.com/S/TRON\">$Corner Growth Acquisition Corp 2(TRON)$ </a> <a href=\"https://laohu8.com/S/SRM\">$SRM Entertainment, Inc.(SRM)$ </a> 前天就辟谣了,老川儿子不会在公司担任职务。","text":"$Corner Growth Acquisition Corp 2(TRON)$ $SRM Entertainment, Inc.(SRM)$ 前天就辟谣了,老川儿子不会在公司担任职务。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/447500306932040","repostId":"2544845939","repostType":2,"repost":{"id":"2544845939","kind":"highlight","weMediaInfo":{"introduction":"追踪全球财经热点,精选影响您财富的资讯,投资理财必备神器!","home_visible":1,"media_name":"华尔街见闻","id":"1084101182","head_image":"https://static.tigerbbs.com/66809d1f5c2e43e2bdf15820c6d6897e"},"pubTimestamp":1750124302,"share":"https://ttm.financial/m/news/2544845939?lang=&edition=full","pubTime":"2025-06-17 09:38","market":"us","language":"zh","title":"孙宇晨要上市了,特朗普小儿子将加入!这只股票隔夜暴涨647%","url":"https://stock-news.laohu8.com/highlight/detail?id=2544845939","media":"华尔街见闻","summary":"币圈最具争议的人物——孙宇晨即将带领他的波场(Tron)借壳上市,壳公司SRM Entertainment股价一夜飙升647%。这笔交易由与特朗普家族关系密切的投资银行Dominari证券操作,Eric Trump预计将在新公司担任职务。四个月前美国SEC还在指控孙宇晨操纵市场,如今他已华丽转身。","content":"<html><head></head><body><p>高调参加完特朗普的币圈晚宴后,加密富豪孙宇晨创立的数字资产平台波场(Tron)要借壳上市了,壳公司隔夜暴涨647%。耐人寻味的是,这背后的操盘方是和特朗普的儿子们关系密切的投行。</p><p>据市场报道,孙宇晨的加密平台波场(Tron)已与纳斯达克上市公司<a href=\"https://laohu8.com/S/SRM\">SRM Entertainment</a>达成反向并购协议。新实体计划注入价值2.1亿美元的代币资产,并更名为“Tron Inc.”。该交易发生在美国证券交易委员会( SEC)暂停对孙宇晨涉嫌市场操纵诉讼的关键时期,且由特朗普家族密切关联的Dominari证券公司操盘。</p><p>本次借壳上市的操盘方Dominari证券公司的总部就位于特朗普大厦,且美国总统特朗普长子小唐纳德(Donald Trump Jr.)与次子埃里克(Eric Trump)已于今年2月加入其母公司<a href=\"https://laohu8.com/S/DOMH\">Dominari Holdings</a>顾问委员会,消息公布前该公司股价580%的异常涨幅曾引发监管关注。知情人士还透露,埃里克预计将在新成立的“Tron Inc”中担任重要职务。</p><p>而 <a href=\"https://laohu8.com/S/SRM\">SRM Entertainment, Inc.</a> 作为壳公司,在并购消息刺激下股价在隔夜一度飙升647%。</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/6ab11ee14f93e3cb85e8f950db41f533\" tg-width=\"560\" tg-height=\"240\"/></p><p>据悉,“Tron Inc”将采用MicroStrategy创始人Michael Saylor的战术,购买并持有Tron代币,将自己打造成一个加杠杆的数字资产投资工具。</p><h2 id=\"id_2505267570\">争议人物的华丽转身</h2><p>孙宇晨长期被视为加密币行业最具争议的人物之一,以博眼球的炒作手段闻名。2019年,他以460万美元拍下与沃伦·巴菲特共进午餐的慈善拍卖,但最后却放了股神的“鸽子”。去年,他又花费620万美元购买了一根贴在墙上的香蕉艺术品,随后当着全世界媒体的面将其吃掉。</p><p>前段时间,他还高调出席特朗普的晚宴。华尔街见闻文章提及,晚宴邀请了220位“特朗普币”的最大持有者,身为“榜一大哥”的孙宇晨成为全场焦点。孙宇晨不仅在晚宴上与特朗普亲密互动,还被隆重邀请上台,戴上特朗普送出的价值10万美元的特朗普品牌金表,抢尽风头。</p><p>而就在前两年,孙宇晨还是美国监管部门重点关注的对象。2023年,美国证券交易委员会指控孙宇晨及其三家公司(包括Tron)销售未注册证券并操纵市场。然而,当特朗普释放出对加密币行业采取宽松监管态度的信号后,<strong>SEC与孙宇晨在今年2月共同向法院提交了暂停诉讼的动议,以探索潜在的和解方案。</strong></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>孙宇晨要上市了,特朗普小儿子将加入!这只股票隔夜暴涨647%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n孙宇晨要上市了,特朗普小儿子将加入!这只股票隔夜暴涨647%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-06-17 09:38 北京时间 <a href=https://wallstreetcn.com/articles/3749237><strong>华尔街见闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>高调参加完特朗普的币圈晚宴后,加密富豪孙宇晨创立的数字资产平台波场(Tron)要借壳上市了,壳公司隔夜暴涨647%。耐人寻味的是,这背后的操盘方是和特朗普的儿子们关系密切的投行。据市场报道,孙宇晨的加密平台波场(Tron)已与纳斯达克上市公司SRM Entertainment达成反向并购协议。新实体计划注入价值2.1亿美元的代币资产,并更名为“Tron Inc.”。该交易发生在美国证券交易委员会(...</p>\n\n<a href=\"https://wallstreetcn.com/articles/3749237\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/8c1218f24aa412245e9defd57717c9d3","relate_stocks":{"SRM":"SRM Entertainment, Inc."},"source_url":"https://wallstreetcn.com/articles/3749237","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2544845939","content_text":"高调参加完特朗普的币圈晚宴后,加密富豪孙宇晨创立的数字资产平台波场(Tron)要借壳上市了,壳公司隔夜暴涨647%。耐人寻味的是,这背后的操盘方是和特朗普的儿子们关系密切的投行。据市场报道,孙宇晨的加密平台波场(Tron)已与纳斯达克上市公司SRM Entertainment达成反向并购协议。新实体计划注入价值2.1亿美元的代币资产,并更名为“Tron Inc.”。该交易发生在美国证券交易委员会( SEC)暂停对孙宇晨涉嫌市场操纵诉讼的关键时期,且由特朗普家族密切关联的Dominari证券公司操盘。本次借壳上市的操盘方Dominari证券公司的总部就位于特朗普大厦,且美国总统特朗普长子小唐纳德(Donald Trump Jr.)与次子埃里克(Eric Trump)已于今年2月加入其母公司Dominari Holdings顾问委员会,消息公布前该公司股价580%的异常涨幅曾引发监管关注。知情人士还透露,埃里克预计将在新成立的“Tron Inc”中担任重要职务。而 SRM Entertainment, Inc. 作为壳公司,在并购消息刺激下股价在隔夜一度飙升647%。据悉,“Tron Inc”将采用MicroStrategy创始人Michael Saylor的战术,购买并持有Tron代币,将自己打造成一个加杠杆的数字资产投资工具。争议人物的华丽转身孙宇晨长期被视为加密币行业最具争议的人物之一,以博眼球的炒作手段闻名。2019年,他以460万美元拍下与沃伦·巴菲特共进午餐的慈善拍卖,但最后却放了股神的“鸽子”。去年,他又花费620万美元购买了一根贴在墙上的香蕉艺术品,随后当着全世界媒体的面将其吃掉。前段时间,他还高调出席特朗普的晚宴。华尔街见闻文章提及,晚宴邀请了220位“特朗普币”的最大持有者,身为“榜一大哥”的孙宇晨成为全场焦点。孙宇晨不仅在晚宴上与特朗普亲密互动,还被隆重邀请上台,戴上特朗普送出的价值10万美元的特朗普品牌金表,抢尽风头。而就在前两年,孙宇晨还是美国监管部门重点关注的对象。2023年,美国证券交易委员会指控孙宇晨及其三家公司(包括Tron)销售未注册证券并操纵市场。然而,当特朗普释放出对加密币行业采取宽松监管态度的信号后,SEC与孙宇晨在今年2月共同向法院提交了暂停诉讼的动议,以探索潜在的和解方案。","news_type":1,"symbols_score_info":{"SRM":1.1}},"isVote":1,"tweetType":1,"viewCount":799,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":444171942282040,"gmtCreate":1749461721868,"gmtModify":1749462176008,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$ </a> 一个全球知名的、多方向的科技前沿企业,如果因为董事长跟总统吵了一架,公司(股价)就不行了,岂不是世界笑话?何况还是曾经帮过大忙的朋友。 民主党那些媒体、团体天天嘲笑、咒骂总统也没见受到什么伤害。","listText":"<a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$ </a> 一个全球知名的、多方向的科技前沿企业,如果因为董事长跟总统吵了一架,公司(股价)就不行了,岂不是世界笑话?何况还是曾经帮过大忙的朋友。 民主党那些媒体、团体天天嘲笑、咒骂总统也没见受到什么伤害。","text":"$特斯拉(TSLA)$ 一个全球知名的、多方向的科技前沿企业,如果因为董事长跟总统吵了一架,公司(股价)就不行了,岂不是世界笑话?何况还是曾经帮过大忙的朋友。 民主党那些媒体、团体天天嘲笑、咒骂总统也没见受到什么伤害。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/444171942282040","isVote":1,"tweetType":1,"viewCount":2240,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":425043270226512,"gmtCreate":1744762022300,"gmtModify":1744767202067,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":" 特朗普的目的是: 高端制造业会回流,比如半导体,中低端制造业全球重构,不再集中在中国,目前来看他可能会在一定程度上达到目的(大部分人看不懂老川,而且小看他)。 作为中国,通过几十年建设起来的制造业千万要想方设法保住,而且规模是面向全球的,产能巨大,从业人口众多,一旦失去要回来就很难了,所以对外贸问题一定要灵活处理,能屈能伸,否则会造成大量外贸企业的极度困难,涉及到几千万人的就业问题,而这几千万人口又会因家庭组合、消费等影响到更大的范围,很多反应都是连锁的,比如有的生产企业它内外贸都做,微利时代,一旦由于外贸砍掉一大块,企业就可能从盈利变成亏损,而亏损企业如果在一定的时间内看不到扭亏的可能性就可能会止损停业,这就不仅仅是影响外贸企业了。","listText":" 特朗普的目的是: 高端制造业会回流,比如半导体,中低端制造业全球重构,不再集中在中国,目前来看他可能会在一定程度上达到目的(大部分人看不懂老川,而且小看他)。 作为中国,通过几十年建设起来的制造业千万要想方设法保住,而且规模是面向全球的,产能巨大,从业人口众多,一旦失去要回来就很难了,所以对外贸问题一定要灵活处理,能屈能伸,否则会造成大量外贸企业的极度困难,涉及到几千万人的就业问题,而这几千万人口又会因家庭组合、消费等影响到更大的范围,很多反应都是连锁的,比如有的生产企业它内外贸都做,微利时代,一旦由于外贸砍掉一大块,企业就可能从盈利变成亏损,而亏损企业如果在一定的时间内看不到扭亏的可能性就可能会止损停业,这就不仅仅是影响外贸企业了。","text":"特朗普的目的是: 高端制造业会回流,比如半导体,中低端制造业全球重构,不再集中在中国,目前来看他可能会在一定程度上达到目的(大部分人看不懂老川,而且小看他)。 作为中国,通过几十年建设起来的制造业千万要想方设法保住,而且规模是面向全球的,产能巨大,从业人口众多,一旦失去要回来就很难了,所以对外贸问题一定要灵活处理,能屈能伸,否则会造成大量外贸企业的极度困难,涉及到几千万人的就业问题,而这几千万人口又会因家庭组合、消费等影响到更大的范围,很多反应都是连锁的,比如有的生产企业它内外贸都做,微利时代,一旦由于外贸砍掉一大块,企业就可能从盈利变成亏损,而亏损企业如果在一定的时间内看不到扭亏的可能性就可能会止损停业,这就不仅仅是影响外贸企业了。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/425043270226512","isVote":1,"tweetType":1,"viewCount":3797,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":406108899242200,"gmtCreate":1740174300529,"gmtModify":1740174301822,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"缺乏核心竞争力","listText":"缺乏核心竞争力","text":"缺乏核心竞争力","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/406108899242200","isVote":1,"tweetType":1,"viewCount":1014,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":382694845264256,"gmtCreate":1734466714301,"gmtModify":1734466716222,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/YHC\">$LQR House Inc.(YHC)$ </a> 是不是要被收购了?好像看到有一个12.20的投票截止日的邮件。","listText":"<a href=\"https://laohu8.com/S/YHC\">$LQR House Inc.(YHC)$ </a> 是不是要被收购了?好像看到有一个12.20的投票截止日的邮件。","text":"$LQR House Inc.(YHC)$ 是不是要被收购了?好像看到有一个12.20的投票截止日的邮件。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/382694845264256","isVote":1,"tweetType":1,"viewCount":2427,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":373933571383448,"gmtCreate":1732321971625,"gmtModify":1732321973693,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"这篇文章不错,转发给大家看看","listText":"这篇文章不错,转发给大家看看","text":"这篇文章不错,转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/373933571383448","repostId":"2484291979","repostType":2,"isVote":1,"tweetType":1,"viewCount":1479,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":367775138468056,"gmtCreate":1730829356527,"gmtModify":1730829359322,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"川普,马斯克必胜!智慧与正义!","listText":"川普,马斯克必胜!智慧与正义!","text":"川普,马斯克必胜!智慧与正义!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/367775138468056","isVote":1,"tweetType":1,"viewCount":1793,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":350784205004984,"gmtCreate":1726666160767,"gmtModify":1726666163099,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"0.25% 大概率是25个基点","listText":"0.25% 大概率是25个基点","text":"0.25% 大概率是25个基点","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/350784205004984","isVote":1,"tweetType":1,"viewCount":1558,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":346326169018432,"gmtCreate":1725589449906,"gmtModify":1725589451898,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"稳定收益的股票","listText":"稳定收益的股票","text":"稳定收益的股票","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/346326169018432","repostId":"2464019648","repostType":2,"repost":{"id":"2464019648","kind":"news","pubTimestamp":1725205009,"share":"https://ttm.financial/m/news/2464019648?lang=&edition=full","pubTime":"2024-09-01 23:36","market":"sh","language":"zh","title":"【华创交运*业绩点评】厦门国贸:1H24归母净利润8.4亿,主业短期承压,持续看好大宗供应链龙头转型广阔空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2464019648","media":"华创交运与供应...","summary":"公司公告2024年半年报业绩:1H24归母净利润8.4亿,同比-47%。具体内容详见华创证券研究所2024年9月1日发布的报告《厦门国贸:1H24归母净利润8.4亿,主业短期承压,持续看好大宗供应链龙头转型广阔空间》法律声明:华创证券研究所定位为面向专业投资者的研究团队,本资料仅适用于经认可的专业投资者,仅供在新媒体背景下研究观点的及时交流。","content":"<html><body><article><p>根据《证券期货投资者适当性管理办法》及配套指引,本资料仅面向华创证券客户中的<a href=\"https://laohu8.com/S/FISI\">金融机构</a>专业投资者,请勿对本资料进行任何形式的转发。若您不是华创证券客户中的金融机构专业投资者,请勿订阅、接收或使用本资料中的信息。本资料难以设置访问权限,若给您造成不便,敬请谅解。感谢您的理解与配合。<strong>公司公告2024年半年报业绩:1H24归母<span>净利润</span>8.4亿,同比-47%。</strong><strong>1)<span>营业收入</span></strong>:1H24实现1952亿元,同比-28%。其中24Q2实现983亿元,同比-34%;环比+1%。<strong>2)<span>毛利</span></strong>:1H24实现35.4亿元,同比+13%,毛利率1.8%,同比+0.7pct。其中24Q2实现19.0亿元,同比+61%,毛利率1.9%,同比+1.1pct。<strong>3)归母净利润</strong>:1H24实现8.4亿元,同比-47%,归母净<span>利率</span>0.4%,同比-0.2pct;其中24Q2实现4.3亿元,同比-49%,归母净利率0.4%,同比-0.1pct。根据公司公告,公司归母净利承压主要由于上年同期公司转让国贸期货和启润资本的部分股权以及主营类金融业务的子公司股权增加了归属于上市公司股东的净利润约2.81亿元;以及报告期国际外部环境复杂严峻、国内有效需求相对疲弱,公司供应链管理业务中部分品种因市场行情因素出现经营业绩下滑。<strong>分业务看,</strong>1H24供应链业务、健康科技业务、房地产与金融服务业务营业收入分别为1946、5.6、0.6亿元,其中供应链业务海外收入为342亿元。<strong>1)供应链业务:</strong>1H24占比99.7%。营业收入同比-27.8%。毛利率为1.7%,同比+0.6pct,主要由于1H24公司在铁矿石、煤炭、原油、木材等多个品种新增拓展长协资源,有效增厚毛利;新能源板块加强产业链布局,合作客户超过200家,其中产业客户占比超过90%;并合资成立湖北国贸新材料有限公司拓展光伏铝型材加工业务。<strong>分品类看,</strong>金属及金属矿产、能源化工、农林牧渔1H24营业收入分别为997、505、423亿元,同比-27.5%、-36.0%、-11.3%;经营货量同比-32.9%、-35.3%、-8.8%;期现结合毛利率分别为1.66%、2.18%、2.11%,同比分别+0.17pts、+0.99pts、+0.92pct。<strong>2)健康科技业务</strong><strong>:</strong>1H24公司健康科技业务实现营业收入5.6亿元,同比增长91.4%,毛利率39.8%,同比+33.89pct。公司医疗器械供应链板块已在上海、河南、湖北、北京、内蒙古设立SPD公司,基本形成全国核心区域SPD业务布局。旗下的微创外科手术整体解决方案提供商派尔特医疗上半年强化新产品研发,新增取得5个新产品的首次注册证书;积极开拓海外市场,已在80多个国家及地区建立了销售网络。1H24派尔特医疗实现营收3.1亿元,同比+33.7%,境外收入占比超45%,归母净利6684万元,同比+108.3%。<strong>3)金融与地产:</strong>1H24金融与地产业务营收0.6亿元,占全部营业收入 0.03%,同比下降97.5%,毛利率同比+22pct。主要由于公司地产结算收入大幅下降所致。自2021年公司转让<a href=\"https://laohu8.com/S/600755\">厦门国贸</a>房地产有限公司和厦门国贸发展有限公司股权之后,公司逐步退出了房地产行业。毛利率提升主要由于1H23金融服务业务中子公司启润资本毛利率较低。<strong>公司持续推动产业化、国际化、数字化战略。</strong><strong>1)延伸产业链布局,打造新增长曲线。</strong>延伸产业链布局,持续开发新兴业务品类及成熟业务板块中的高附加值品类,积极布局天然气、石英砂/石等新品种资源,打造新增长曲线。<strong>2)深化国际化发展,推动关键物流节点布局。</strong>公司已在东南亚、中亚、中东、南美等地设立20余家主要子公司,海外团队建设逐步完善。1H24公司新设立越南平台公司,主要拓展钢铁业务;新设立德国办事处,积极拓展新能源业务。截至1H24公司在意大利、赞比亚、坦桑尼亚等国家签约16个海外仓;海外物流项目稳步发展,西非海上转运项目完成过驳转运总量近500万吨,印尼ARK浮吊和驳船作业量总计超600万吨。<strong>3)迭代数字化应用,持续提升经营管理效能。</strong>1H24公司多个供应链业务品种数字化系统实现迭代升级,新增上线煤炭业务数字化系统,持续提升经营管理效能,不断强化中后台管理能力;截至1H24公司“国贸云链”累计订单超8万笔,成交金额超260亿元;“金贸通”平台客户累计用信约25亿元,与金融机构合作开发的“未来提货权”供应链金融产品实现首笔成功放款。<strong>我们持续看好公司作为大宗供应链龙头转型逻辑逐步兑现与公司战略聚焦带来的价值提升。</strong>我们此前提出了“纵向流量+横向变现”的投资研究框架:1)收入端,纵向流量稳定增长:格局红利、龙头份额集中+新品类扩张。2)利润率端,提质增效,横向变现能力持续增强:高利润率品类拓展+物流布局带来高周转降本增效+高利润率一体化项目运营丰富收益。<strong>投资建议:</strong><strong>1)盈利预测:</strong>基于大宗商品需求恢复弱于预期,我们预计2024-2026年盈利预测分别为18.6、20.4、22.8亿元,对应EPS分别为0.84、0.92、1.03元,对应PE分别为7、6、6倍。<strong>2)高股息品种。</strong>公司在23年提升<span>分红</span>比例至57.6%,作为低估值、高股息标的,我们认为一旦市场对经济预期转暖,公司将具备进可攻、退可守的强配置价值。维持“强推”评级。<strong>风险提示:大宗商品需求大幅下降,经济出现下滑。</strong></p><img src=\"https://fid-75186.picgzc.qpic.cn/20240901233758348v163r9e8j64mims\"/><p><strong>具体内容详见华创证券研究所2024年9月1日发布的报告</strong>《<strong>厦门国贸:1H24归母净利润8.4亿,主业短期承压,持续看好大宗供应链龙头转型广阔空间》</strong></p><p><strong>法律声明:</strong>华创证券研究所定位为面向专业投资者的研究团队,本资料仅适用于经认可的专业投资者,仅供在新媒体背景下研究观点的及时交流。华创证券不因任何订阅本资料的行为而将订阅人视为公司的客户。普通投资者若使用本资料,有可能因缺乏解读服务而对报告中的关键假设、评级、目标价等内容产生理解上的歧义,进而造成投资损失。本资料来自华创证券研究所已经发布的研究报告,若对报告的摘编产生歧义,应以报告发布当日的完整内容为准。须注意的是,本资料仅代表报告发布当日的判断,相关的分析意见及推测可能会根据华创证券研究所后续发布的研究报告在不发出通知的情形下做出更改。华创证券的其他业务部门或附属机构可能独立做出与本资料的意见或建议不一致的投资决策。本资料所指的证券或金融工具的价格、价值及收入可涨可跌,以往的表现不应作为日后表现的显示及担保。本资料仅供订阅人参考之用,不是或不应被视为出售、购买或认购证券或其它金融工具的要约或要约邀请。订阅人不应单纯依靠本资料的信息而取代自身的独立判断,应自主作出投资决策并自行承担投资风险。华创证券不对使用本资料涉及的信息所产生的任何直接或间接损失或与此有关的其他损失承担任何责任。本资料所载的证券市场研究信息通常基于特定的假设条件,提供中长期的价值判断,或者依据“相对指数表现”给出投资建议,并不涉及对具体证券或金融工具在具体价位、具体时点、具体市场表现的判断,因此不能够等同于带有针对性的、指导具体投资的操作意见。普通个人投资者如需使用本资料,须寻求专业投资顾问的指导及相关的后续解读服务。若因不当使用相关信息而造成任何直接或间接损失,华创证券对此不承担任何形式的责任。未经华创证券事先书面授权,任何机构或个人不得以任何方式修改、发送或者复制本资料的内容。华创证券未曾对任何网络、平面媒体做出过允许转载的日常授权。除经华创证券认可的媒体约稿等情况外,其他一切转载行为均属违法。如因侵权行为给华创证券造成任何直接或间接的损失,华创证券保留追究相关法律责任的权利。订阅人若有任何疑问,或欲获得完整报告内容,敬请联系华创证券的机构销售部门,或者发送邮件至jiedu@hcyjs.com。</p></article></body></html>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【华创交运*业绩点评】厦门国贸:1H24归母净利润8.4亿,主业短期承压,持续看好大宗供应链龙头转型广阔空间</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【华创交运*业绩点评】厦门国贸:1H24归母净利润8.4亿,主业短期承压,持续看好大宗供应链龙头转型广阔空间\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-01 23:36 北京时间 <a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024090123380595d95581&s=b><strong>华创交运与供应...</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>根据《证券期货投资者适当性管理办法》及配套指引,本资料仅面向华创证券客户中的金融机构专业投资者,请勿对本资料进行任何形式的转发。若您不是华创证券客户中的金融机构专业投资者,请勿订阅、接收或使用本资料中的信息。本资料难以设置访问权限,若给您造成不便,敬请谅解。感谢您的理解与配合。公司公告2024年半年报业绩:1H24归母净利润8.4亿,同比-47%。1)营业收入:1H24实现1952亿元,同比-...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024090123380595d95581&s=b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"600755":"厦门国贸"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024090123380595d95581&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2464019648","content_text":"根据《证券期货投资者适当性管理办法》及配套指引,本资料仅面向华创证券客户中的金融机构专业投资者,请勿对本资料进行任何形式的转发。若您不是华创证券客户中的金融机构专业投资者,请勿订阅、接收或使用本资料中的信息。本资料难以设置访问权限,若给您造成不便,敬请谅解。感谢您的理解与配合。公司公告2024年半年报业绩:1H24归母净利润8.4亿,同比-47%。1)营业收入:1H24实现1952亿元,同比-28%。其中24Q2实现983亿元,同比-34%;环比+1%。2)毛利:1H24实现35.4亿元,同比+13%,毛利率1.8%,同比+0.7pct。其中24Q2实现19.0亿元,同比+61%,毛利率1.9%,同比+1.1pct。3)归母净利润:1H24实现8.4亿元,同比-47%,归母净利率0.4%,同比-0.2pct;其中24Q2实现4.3亿元,同比-49%,归母净利率0.4%,同比-0.1pct。根据公司公告,公司归母净利承压主要由于上年同期公司转让国贸期货和启润资本的部分股权以及主营类金融业务的子公司股权增加了归属于上市公司股东的净利润约2.81亿元;以及报告期国际外部环境复杂严峻、国内有效需求相对疲弱,公司供应链管理业务中部分品种因市场行情因素出现经营业绩下滑。分业务看,1H24供应链业务、健康科技业务、房地产与金融服务业务营业收入分别为1946、5.6、0.6亿元,其中供应链业务海外收入为342亿元。1)供应链业务:1H24占比99.7%。营业收入同比-27.8%。毛利率为1.7%,同比+0.6pct,主要由于1H24公司在铁矿石、煤炭、原油、木材等多个品种新增拓展长协资源,有效增厚毛利;新能源板块加强产业链布局,合作客户超过200家,其中产业客户占比超过90%;并合资成立湖北国贸新材料有限公司拓展光伏铝型材加工业务。分品类看,金属及金属矿产、能源化工、农林牧渔1H24营业收入分别为997、505、423亿元,同比-27.5%、-36.0%、-11.3%;经营货量同比-32.9%、-35.3%、-8.8%;期现结合毛利率分别为1.66%、2.18%、2.11%,同比分别+0.17pts、+0.99pts、+0.92pct。2)健康科技业务:1H24公司健康科技业务实现营业收入5.6亿元,同比增长91.4%,毛利率39.8%,同比+33.89pct。公司医疗器械供应链板块已在上海、河南、湖北、北京、内蒙古设立SPD公司,基本形成全国核心区域SPD业务布局。旗下的微创外科手术整体解决方案提供商派尔特医疗上半年强化新产品研发,新增取得5个新产品的首次注册证书;积极开拓海外市场,已在80多个国家及地区建立了销售网络。1H24派尔特医疗实现营收3.1亿元,同比+33.7%,境外收入占比超45%,归母净利6684万元,同比+108.3%。3)金融与地产:1H24金融与地产业务营收0.6亿元,占全部营业收入 0.03%,同比下降97.5%,毛利率同比+22pct。主要由于公司地产结算收入大幅下降所致。自2021年公司转让厦门国贸房地产有限公司和厦门国贸发展有限公司股权之后,公司逐步退出了房地产行业。毛利率提升主要由于1H23金融服务业务中子公司启润资本毛利率较低。公司持续推动产业化、国际化、数字化战略。1)延伸产业链布局,打造新增长曲线。延伸产业链布局,持续开发新兴业务品类及成熟业务板块中的高附加值品类,积极布局天然气、石英砂/石等新品种资源,打造新增长曲线。2)深化国际化发展,推动关键物流节点布局。公司已在东南亚、中亚、中东、南美等地设立20余家主要子公司,海外团队建设逐步完善。1H24公司新设立越南平台公司,主要拓展钢铁业务;新设立德国办事处,积极拓展新能源业务。截至1H24公司在意大利、赞比亚、坦桑尼亚等国家签约16个海外仓;海外物流项目稳步发展,西非海上转运项目完成过驳转运总量近500万吨,印尼ARK浮吊和驳船作业量总计超600万吨。3)迭代数字化应用,持续提升经营管理效能。1H24公司多个供应链业务品种数字化系统实现迭代升级,新增上线煤炭业务数字化系统,持续提升经营管理效能,不断强化中后台管理能力;截至1H24公司“国贸云链”累计订单超8万笔,成交金额超260亿元;“金贸通”平台客户累计用信约25亿元,与金融机构合作开发的“未来提货权”供应链金融产品实现首笔成功放款。我们持续看好公司作为大宗供应链龙头转型逻辑逐步兑现与公司战略聚焦带来的价值提升。我们此前提出了“纵向流量+横向变现”的投资研究框架:1)收入端,纵向流量稳定增长:格局红利、龙头份额集中+新品类扩张。2)利润率端,提质增效,横向变现能力持续增强:高利润率品类拓展+物流布局带来高周转降本增效+高利润率一体化项目运营丰富收益。投资建议:1)盈利预测:基于大宗商品需求恢复弱于预期,我们预计2024-2026年盈利预测分别为18.6、20.4、22.8亿元,对应EPS分别为0.84、0.92、1.03元,对应PE分别为7、6、6倍。2)高股息品种。公司在23年提升分红比例至57.6%,作为低估值、高股息标的,我们认为一旦市场对经济预期转暖,公司将具备进可攻、退可守的强配置价值。维持“强推”评级。风险提示:大宗商品需求大幅下降,经济出现下滑。具体内容详见华创证券研究所2024年9月1日发布的报告《厦门国贸:1H24归母净利润8.4亿,主业短期承压,持续看好大宗供应链龙头转型广阔空间》法律声明:华创证券研究所定位为面向专业投资者的研究团队,本资料仅适用于经认可的专业投资者,仅供在新媒体背景下研究观点的及时交流。华创证券不因任何订阅本资料的行为而将订阅人视为公司的客户。普通投资者若使用本资料,有可能因缺乏解读服务而对报告中的关键假设、评级、目标价等内容产生理解上的歧义,进而造成投资损失。本资料来自华创证券研究所已经发布的研究报告,若对报告的摘编产生歧义,应以报告发布当日的完整内容为准。须注意的是,本资料仅代表报告发布当日的判断,相关的分析意见及推测可能会根据华创证券研究所后续发布的研究报告在不发出通知的情形下做出更改。华创证券的其他业务部门或附属机构可能独立做出与本资料的意见或建议不一致的投资决策。本资料所指的证券或金融工具的价格、价值及收入可涨可跌,以往的表现不应作为日后表现的显示及担保。本资料仅供订阅人参考之用,不是或不应被视为出售、购买或认购证券或其它金融工具的要约或要约邀请。订阅人不应单纯依靠本资料的信息而取代自身的独立判断,应自主作出投资决策并自行承担投资风险。华创证券不对使用本资料涉及的信息所产生的任何直接或间接损失或与此有关的其他损失承担任何责任。本资料所载的证券市场研究信息通常基于特定的假设条件,提供中长期的价值判断,或者依据“相对指数表现”给出投资建议,并不涉及对具体证券或金融工具在具体价位、具体时点、具体市场表现的判断,因此不能够等同于带有针对性的、指导具体投资的操作意见。普通个人投资者如需使用本资料,须寻求专业投资顾问的指导及相关的后续解读服务。若因不当使用相关信息而造成任何直接或间接损失,华创证券对此不承担任何形式的责任。未经华创证券事先书面授权,任何机构或个人不得以任何方式修改、发送或者复制本资料的内容。华创证券未曾对任何网络、平面媒体做出过允许转载的日常授权。除经华创证券认可的媒体约稿等情况外,其他一切转载行为均属违法。如因侵权行为给华创证券造成任何直接或间接的损失,华创证券保留追究相关法律责任的权利。订阅人若有任何疑问,或欲获得完整报告内容,敬请联系华创证券的机构销售部门,或者发送邮件至jiedu@hcyjs.com。","news_type":1,"symbols_score_info":{"600755":1}},"isVote":1,"tweetType":1,"viewCount":1629,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":337852408566032,"gmtCreate":1723504153275,"gmtModify":1723504154727,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"为人类健康努力<a href=\"https://laohu8.com/S/INAB\">$IN8bio, Inc.(INAB)$ </a> ","listText":"为人类健康努力<a href=\"https://laohu8.com/S/INAB\">$IN8bio, Inc.(INAB)$ </a> ","text":"为人类健康努力$IN8bio, Inc.(INAB)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/337852408566032","repostId":"2458409604","repostType":2,"repost":{"id":"2458409604","kind":"highlight","pubTimestamp":1723464300,"share":"https://ttm.financial/m/news/2458409604?lang=&edition=full","pubTime":"2024-08-12 20:05","market":"us","language":"en","title":"IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100","url":"https://stock-news.laohu8.com/highlight/detail?id=2458409604","media":"GlobeNewswire","summary":"Received FDA guidance on the registrational path for INB-100 in acute myeloid leukemia , an investigational allogeneic gamma-delta T cell therapy, with IND submission anticipated in Q1 2025.Early clinical data from investigator sponsored trials demonstrates prolonged relapse-free survival across both AML and glioblastoma programs, compared to current standard-of-care, with both programs advancing to Phase 2 clinical development.Solidifying position as a leader in gamma-delta T cell therapy for oncology as the first company to report improvements in relapse-free survival in both solid and hematological cancers with allogeneic or autologous gamma-delta T cells.Conference call and webcast to be hosted today at 8:30 a.m. ET. Use this link to participate. A listen-only version of the webcast is available here.Every AML patient treated with INB-100 remains in complete remission , and patients across both trials have exceeded expected progression-free survival to date. These data continue t","content":"<html><body><img hspace=\"5\" src=\"https://s.yimg.com/uu/api/res/1.2/rUdegrSOeOFk4PkDGTiJoQ--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/2eaff8c6754066d4f7498c1179b53d18\" title=\"IN8bioLogo.jpg\" vspace=\"5\"/>\n<ul>\n<li>Received FDA guidance on the registrational path for INB-100 in acute myeloid leukemia (AML), an investigational allogeneic gamma-delta T cell therapy, with IND submission anticipated in Q1 2025.</li>\n</ul>\n<ul>\n<li>Early clinical data from investigator sponsored trials demonstrates prolonged relapse-free survival across both AML and glioblastoma (GBM) programs, compared to current standard-of-care, with both programs advancing to Phase 2 clinical development.</li>\n</ul>\n<ul type=\"disc\">\n<li>Solidifying position as a leader in gamma-delta T cell therapy for oncology as the first company to report improvements in relapse-free survival in both solid and hematological cancers with allogeneic or autologous gamma-delta T cells.</li>\n</ul>\n<ul type=\"disc\">\n<li>Conference call and webcast to be hosted today at 8:30 a.m. ET. Use this link to participate. A listen-only version of the webcast is available here.<br/></li>\n</ul>\n<p>NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- <strong><u><a href=\"https://laohu8.com/S/INAB\">IN8bio, Inc.</a></u></strong><strong> (Nasdaq: INAB)</strong>, a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer, today announced updated positive clinical data from both of the Company’s Phase 1 investigator-sponsored trials of INB-100 for hematological malignancies and INB-200 for GBM. The Company has also completed a Type B meeting with the FDA and received guidance on the registrational path to advance INB-100 for the treatment of AML.</p>\n<p>Every AML patient treated with INB-100 remains in complete remission (CR), and patients across both trials have exceeded expected progression-free survival (PFS) to date. These data continue to demonstrate the broad clinical potential of gamma-delta T cells for difficult-to-treat cancers and provides support for the advancement of these therapies into Phase 2 trials.</p>\n<p>As of August 1, 2024, no new relapses have been reported since the clinical updates provided at the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA) annual meetings.</p>\n<p>“Our gamma-delta T cell therapies, engineered with our industry-leading manufacturing technology, continue to demonstrate their potential to eliminate residual cancer cells and to revolutionize cancer treatment,” said William Ho, CEO and co-founder of IN8bio. “The safety profile of gamma-delta T cells has been manageable and well-tolerated across both indications with no significant cell therapy-related toxicities reported to date in any patients across these Phase 1 trials.”</p>\n<p><strong>Program Details as of August 1, 2024:</strong></p>\n<p><strong>INB-100 for AML </strong></p>\n<ul type=\"disc\">\n<li><strong>FDA Guidance on Registrational Program</strong>: Following a Type B meeting with the FDA earlier this summer, IN8bio received regulatory guidance on advancing INB-100 for the treatment of AML as a post-transplant maintenance therapy, with relapse-free survival as the primary endpoint. To date, 100% of AML patients treated with INB-100 are in long-term CR, providing a promising path for the registrational trial. IN8bio plans to submit an Investigational New Drug (IND) application to the FDA in Q1 2025. Pending clearance, the Company could initiate a registrational trial for AML in 2025.<br/></li>\n<li><strong>100% 1-year Relapse-Free Survival:</strong> All patients dosed in the Phase 1 investigator-sponsored trial continue to demonstrate relapse-free survival beyond one year. These patients are mostly classified as high-risk, a category where ~25% would typically be expected to relapse within 100 days post-transplant and up to 50% by one year.<br/></li>\n<li><strong>AML Patient Outcomes:</strong> 100% of AML patients remain relapse-free after receiving their dose of INB-100. There have been no new relapses reported since the last update with a data cut-off on May 15, 2024. The previously reported patients with other leukemic diagnoses (ALL and MDS/MPN overlap with concurrent TP53 mutations) who relapsed are still alive. The proposed Phase 2 registrational trial will only include patients with AML, a highly aggressive leukemia with high relapse rates, where Phase 1 results to date have shown the most promising long-term responses.<br/></li>\n<li><strong>Expansion Cohort: </strong>Enrollment in expansion cohort is ongoing, and all treated patients remain in CR, with several having been evaluated for at least 90 days post-transplant and the longest nearing seven months. Full enrollment of the 10-patient expansion cohort is expected by the end of 2024, with long-term follow up results anticipated in 2025.<br/></li>\n<li><strong>Gamma-Delta T Cell Persistence:</strong> A significant increase in dose-dependent long-term expansion and persistence of circulating gamma-delta T cells continues to be observed up to day 365 post-infusion. This marks the first instance of an allogeneic cellular therapy demonstrating both persistence and expansion over this extended time frame. Cell persistence potentially allows for the gamma-delta T cells to conduct longer immune surveillance to prevent relapse.<br/></li>\n</ul>\n<p><strong>INB-200 for GBM</strong></p>\n<ul type=\"disc\">\n<li><strong>Novel Cellular Therapy Approach: </strong>IN8bio’s proprietary drug-resistant immunotherapy (DRI) technology combines standard-of-care chemotherapy with gene-edited, chemotherapy-resistant gamma-delta T cells. Initial data points to a potential dose response across the three cohorts with dose-escalation ranging from a single dose in cohort 1, three doses in cohort 2, and up to six repeat doses in cohort 3. All patients in cohort 1 eventually relapsed. There have been no new relapses with a range of remission from 9.5 to 37.9 months in cohorts 2 and 3 to date. Multiple patients in these higher repeat dose cohorts have now exceeded the overall survival expected with standard-of-care alone relative to historical data. <br/><br/><br/></li>\n<li><strong>MGMT-unmethylated GBM patients</strong>: Several patients in this group, who are typically poor responders and generally unresponsive to chemotherapy, have remained in remission longer than expected. Notably, one patient who received six doses of INB-200 has been in remission for over a year. Updated clinical data from this trial is expected to be presented in Q4 2024.<br/><br/><br/></li>\n<li><strong>INB-400 in Phase 2 trial:</strong> This study is investigating six doses of autologous gamma-delta T cells in front-line GBM treatment in combination with standard-of-care. The trial is actively enrolling and treating patients at multiple leading cancer centers across the United States.<br/></li>\n</ul>\n<p>Mr. Ho, also commented, “These therapies take advantage of the gamma-delta T cells’ natural ability to target the heterogeneity of cancers, prevent immune escape and disease relapse. Multiple patients have now remained in progression-free remissions longer than expected with many now exceeding expected overall survival, based on historical data. The safety profile and long-term remissions observed with both INB-100 and INB-200, now exceeding three years, across two difficult indications, suggest a significant potential advancement for cellular therapies for cancer. With these compelling results to date, IN8bio stands at the forefront of innovation in oncology and gamma-delta T cell development.”</p>\n<p><strong>Conference Call Details</strong></p>\n<p>IN8bio will host a conference call and webcast today, Monday, August 12, 2024, at 8:30 am ET. The webcast can be accessed by clicking this link and can also be accessed on the Events & Presentations page of the Company’s website. To participate in the live call, please register using this link. It is recommended that participants register at least 15 minutes in advance of the call. Once registered, participants will be informed of the dial-in number and will be provided a unique PIN.</p>\n<p><strong>About IN8bio</strong></p>\n<p>IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program INB-400 is in a Phase 2 trial in GBM. Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit <u>www.IN8bio.com</u>.</p>\n<p><strong>Forward Looking Statements</strong></p>\n<p>This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: IN8bio’s ability to continue advancing our gamma-delta T-cell programs; the broad clinical potential of gamma-delta T cell therapies to revolutionize cancer treatment; the ability of INB-100 and INB-200 to target difficult to treat cancers and to continue to demonstrate an improvement in relapse free survival across both AML and GBM; the timing and success of IN8bio’s interactions with regulatory agencies, including the FDA; and IN8bio’s ability to achieve anticipated milestones, including expected presentations and data readouts from its trials, enrollment of additional patients in its clinical trials, advancement of clinical development plans and submission of INDs. IN8bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as IN8bio’s ability to meet anticipated deadlines and milestones, presented by public health crises as well as rising inflation and regulatory developments; uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of IN8bio’s product candidates; the risk that IN8bio may not realize the intended benefits of its DeltEx platform; availability and timing of results from preclinical studies and clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of IN8bio’s product candidates; expectations for regulatory approvals to conduct trials or to market products; IN8bio’s reliance on third parties, including licensors and clinical research organizations; and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, are described in greater detail in the section entitled “Risk Factors” in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 8, 2024, as well as in other filings IN8bio may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and IN8bio expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events,</p>\n<p>Corporate Contact:</p>\n<p>IN8bio, Inc.<br/>Glenn Schulman, PharmD, MPH<br/>203.494.7411<br/>gdschulman@IN8bio.com<br/><br/><br/></p>\n<p>Investors Contact<br/>Meru Advisors<br/>Lee M. Stern<br/>lstern@meruadvisors.com<br/><br/><br/></p>\n<p>Media Contact<br/>Kimberly Ha<br/>KKH Advisors<br/>917.291.5744<br/>kimberly.ha@kkhadvisors.com<br/><br/><br/><br/></p>\n<br/></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-12 20:05 GMT+8 <a href=https://finance.yahoo.com/news/in8bio-solidifies-position-clinical-leader-120500289.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Received FDA guidance on the registrational path for INB-100 in acute myeloid leukemia (AML), an investigational allogeneic gamma-delta T cell therapy, with IND submission anticipated in Q1 2025.\n\n\n...</p>\n\n<a href=\"https://finance.yahoo.com/news/in8bio-solidifies-position-clinical-leader-120500289.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/q1aLUvDIPjpm1dRcpp7cyw--~B/aD01NjM7dz0xMTM2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/5d6ee3f35b7ad09d7aba87e526c16190","relate_stocks":{"INAB":"IN8bio, Inc.","BK4195":"互助储蓄与抵押信贷金融服务","BK4139":"生物科技","DRI":"达登饭店","BK4161":"工业机械","BK4585":"ETF&股票定投概念","BK4504":"桥水持仓","PFS":"Provident Financial Services Inc","CR":"crane","INB":"Cohen & Steers Global Income Bui","BK4209":"餐馆","BK4211":"区域性银行","BK4588":"碎股","BK4539":"次新股"},"source_url":"https://finance.yahoo.com/news/in8bio-solidifies-position-clinical-leader-120500289.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2458409604","content_text":"Received FDA guidance on the registrational path for INB-100 in acute myeloid leukemia (AML), an investigational allogeneic gamma-delta T cell therapy, with IND submission anticipated in Q1 2025.\n\n\nEarly clinical data from investigator sponsored trials demonstrates prolonged relapse-free survival across both AML and glioblastoma (GBM) programs, compared to current standard-of-care, with both programs advancing to Phase 2 clinical development.\n\n\nSolidifying position as a leader in gamma-delta T cell therapy for oncology as the first company to report improvements in relapse-free survival in both solid and hematological cancers with allogeneic or autologous gamma-delta T cells.\n\n\nConference call and webcast to be hosted today at 8:30 a.m. ET. Use this link to participate. A listen-only version of the webcast is available here.\n\nNEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer, today announced updated positive clinical data from both of the Company’s Phase 1 investigator-sponsored trials of INB-100 for hematological malignancies and INB-200 for GBM. The Company has also completed a Type B meeting with the FDA and received guidance on the registrational path to advance INB-100 for the treatment of AML.\nEvery AML patient treated with INB-100 remains in complete remission (CR), and patients across both trials have exceeded expected progression-free survival (PFS) to date. These data continue to demonstrate the broad clinical potential of gamma-delta T cells for difficult-to-treat cancers and provides support for the advancement of these therapies into Phase 2 trials.\nAs of August 1, 2024, no new relapses have been reported since the clinical updates provided at the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA) annual meetings.\n“Our gamma-delta T cell therapies, engineered with our industry-leading manufacturing technology, continue to demonstrate their potential to eliminate residual cancer cells and to revolutionize cancer treatment,” said William Ho, CEO and co-founder of IN8bio. “The safety profile of gamma-delta T cells has been manageable and well-tolerated across both indications with no significant cell therapy-related toxicities reported to date in any patients across these Phase 1 trials.”\nProgram Details as of August 1, 2024:\nINB-100 for AML \n\nFDA Guidance on Registrational Program: Following a Type B meeting with the FDA earlier this summer, IN8bio received regulatory guidance on advancing INB-100 for the treatment of AML as a post-transplant maintenance therapy, with relapse-free survival as the primary endpoint. To date, 100% of AML patients treated with INB-100 are in long-term CR, providing a promising path for the registrational trial. IN8bio plans to submit an Investigational New Drug (IND) application to the FDA in Q1 2025. Pending clearance, the Company could initiate a registrational trial for AML in 2025.\n100% 1-year Relapse-Free Survival: All patients dosed in the Phase 1 investigator-sponsored trial continue to demonstrate relapse-free survival beyond one year. These patients are mostly classified as high-risk, a category where ~25% would typically be expected to relapse within 100 days post-transplant and up to 50% by one year.\nAML Patient Outcomes: 100% of AML patients remain relapse-free after receiving their dose of INB-100. There have been no new relapses reported since the last update with a data cut-off on May 15, 2024. The previously reported patients with other leukemic diagnoses (ALL and MDS/MPN overlap with concurrent TP53 mutations) who relapsed are still alive. The proposed Phase 2 registrational trial will only include patients with AML, a highly aggressive leukemia with high relapse rates, where Phase 1 results to date have shown the most promising long-term responses.\nExpansion Cohort: Enrollment in expansion cohort is ongoing, and all treated patients remain in CR, with several having been evaluated for at least 90 days post-transplant and the longest nearing seven months. Full enrollment of the 10-patient expansion cohort is expected by the end of 2024, with long-term follow up results anticipated in 2025.\nGamma-Delta T Cell Persistence: A significant increase in dose-dependent long-term expansion and persistence of circulating gamma-delta T cells continues to be observed up to day 365 post-infusion. This marks the first instance of an allogeneic cellular therapy demonstrating both persistence and expansion over this extended time frame. Cell persistence potentially allows for the gamma-delta T cells to conduct longer immune surveillance to prevent relapse.\n\nINB-200 for GBM\n\nNovel Cellular Therapy Approach: IN8bio’s proprietary drug-resistant immunotherapy (DRI) technology combines standard-of-care chemotherapy with gene-edited, chemotherapy-resistant gamma-delta T cells. Initial data points to a potential dose response across the three cohorts with dose-escalation ranging from a single dose in cohort 1, three doses in cohort 2, and up to six repeat doses in cohort 3. All patients in cohort 1 eventually relapsed. There have been no new relapses with a range of remission from 9.5 to 37.9 months in cohorts 2 and 3 to date. Multiple patients in these higher repeat dose cohorts have now exceeded the overall survival expected with standard-of-care alone relative to historical data. \nMGMT-unmethylated GBM patients: Several patients in this group, who are typically poor responders and generally unresponsive to chemotherapy, have remained in remission longer than expected. Notably, one patient who received six doses of INB-200 has been in remission for over a year. Updated clinical data from this trial is expected to be presented in Q4 2024.\nINB-400 in Phase 2 trial: This study is investigating six doses of autologous gamma-delta T cells in front-line GBM treatment in combination with standard-of-care. The trial is actively enrolling and treating patients at multiple leading cancer centers across the United States.\n\nMr. Ho, also commented, “These therapies take advantage of the gamma-delta T cells’ natural ability to target the heterogeneity of cancers, prevent immune escape and disease relapse. Multiple patients have now remained in progression-free remissions longer than expected with many now exceeding expected overall survival, based on historical data. The safety profile and long-term remissions observed with both INB-100 and INB-200, now exceeding three years, across two difficult indications, suggest a significant potential advancement for cellular therapies for cancer. With these compelling results to date, IN8bio stands at the forefront of innovation in oncology and gamma-delta T cell development.”\nConference Call Details\nIN8bio will host a conference call and webcast today, Monday, August 12, 2024, at 8:30 am ET. The webcast can be accessed by clicking this link and can also be accessed on the Events & Presentations page of the Company’s website. To participate in the live call, please register using this link. It is recommended that participants register at least 15 minutes in advance of the call. Once registered, participants will be informed of the dial-in number and will be provided a unique PIN.\nAbout IN8bio\nIN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program INB-400 is in a Phase 2 trial in GBM. Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit www.IN8bio.com.\nForward Looking Statements\nThis press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: IN8bio’s ability to continue advancing our gamma-delta T-cell programs; the broad clinical potential of gamma-delta T cell therapies to revolutionize cancer treatment; the ability of INB-100 and INB-200 to target difficult to treat cancers and to continue to demonstrate an improvement in relapse free survival across both AML and GBM; the timing and success of IN8bio’s interactions with regulatory agencies, including the FDA; and IN8bio’s ability to achieve anticipated milestones, including expected presentations and data readouts from its trials, enrollment of additional patients in its clinical trials, advancement of clinical development plans and submission of INDs. IN8bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as IN8bio’s ability to meet anticipated deadlines and milestones, presented by public health crises as well as rising inflation and regulatory developments; uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of IN8bio’s product candidates; the risk that IN8bio may not realize the intended benefits of its DeltEx platform; availability and timing of results from preclinical studies and clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of IN8bio’s product candidates; expectations for regulatory approvals to conduct trials or to market products; IN8bio’s reliance on third parties, including licensors and clinical research organizations; and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, are described in greater detail in the section entitled “Risk Factors” in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 8, 2024, as well as in other filings IN8bio may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and IN8bio expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events,\nCorporate Contact:\nIN8bio, Inc.Glenn Schulman, PharmD, MPH203.494.7411gdschulman@IN8bio.com\nInvestors ContactMeru AdvisorsLee M. Sternlstern@meruadvisors.com\nMedia ContactKimberly HaKKH Advisors917.291.5744kimberly.ha@kkhadvisors.com","news_type":1,"symbols_score_info":{"CR":1,"DRI":1,"INAB":1,"INB":1,"PFS":1}},"isVote":1,"tweetType":1,"viewCount":2312,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":314386985058568,"gmtCreate":1717785958186,"gmtModify":1717785961533,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/APP\">$AppLovin Corporation(APP)$ </a>现在到了收购<a href=\"https://laohu8.com/S/U\">$Unity Software Inc.(U)$ </a>最好的时机,再度出手吧!!一股换两股甚至2.5股,所有持有<a href=\"https://laohu8.com/S/U\">$Unity Software Inc.(U)$ </a>的人都愿意!","listText":"<a href=\"https://laohu8.com/S/APP\">$AppLovin Corporation(APP)$ </a>现在到了收购<a href=\"https://laohu8.com/S/U\">$Unity Software Inc.(U)$ </a>最好的时机,再度出手吧!!一股换两股甚至2.5股,所有持有<a href=\"https://laohu8.com/S/U\">$Unity Software Inc.(U)$ </a>的人都愿意!","text":"$AppLovin Corporation(APP)$ 现在到了收购$Unity Software Inc.(U)$ 最好的时机,再度出手吧!!一股换两股甚至2.5股,所有持有$Unity Software Inc.(U)$ 的人都愿意!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/314386985058568","isVote":1,"tweetType":1,"viewCount":2595,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":285643779698696,"gmtCreate":1710755572963,"gmtModify":1710755574220,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AIXI\">$小i机器人(AIXI)$ </a>马斯克开源人工智能大模型对AIxi是特大利好呀!!!刚好用于落地做应用市场,好好表现一下!","listText":"<a href=\"https://laohu8.com/S/AIXI\">$小i机器人(AIXI)$ </a>马斯克开源人工智能大模型对AIxi是特大利好呀!!!刚好用于落地做应用市场,好好表现一下!","text":"$小i机器人(AIXI)$ 马斯克开源人工智能大模型对AIxi是特大利好呀!!!刚好用于落地做应用市场,好好表现一下!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/285643779698696","isVote":1,"tweetType":1,"viewCount":5011,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":254282098028656,"gmtCreate":1703116987281,"gmtModify":1703116989705,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"分析的通透","listText":"分析的通透","text":"分析的通透","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/254282098028656","repostId":"2391761082","repostType":2,"isVote":1,"tweetType":1,"viewCount":2815,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":224667246805064,"gmtCreate":1695858491945,"gmtModify":1695858493809,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":" 先讲个故事: 那个人太不像话了,以前每次碰到他都会给5个刀给我,从昨天开始居然说他也要向家人交代,以后每次只能给我2.5刀了!要是有给的更多的人,真不想碰到他了,有吗?居然还是他给的最多![捂脸] <a href=\"https://laohu8.com/S/U\">$Unity Software Inc.(U)$ </a> 一个公司上市了就像一个人结婚了,从此有了对股东和家人的责任,年年花天酒地、入不敷出那是不行的,一个全球占最大份额的全平台游戏引擎股价从200多跌到20多,说明它原先够优秀够廉价,居然不准他为了盈利涨一点点价?何况涨价后还是最便宜的,骂他不跟用户充分沟通,那些大用户也没沟通翻脸不认人破口大骂就有理了?","listText":" 先讲个故事: 那个人太不像话了,以前每次碰到他都会给5个刀给我,从昨天开始居然说他也要向家人交代,以后每次只能给我2.5刀了!要是有给的更多的人,真不想碰到他了,有吗?居然还是他给的最多![捂脸] <a href=\"https://laohu8.com/S/U\">$Unity Software Inc.(U)$ </a> 一个公司上市了就像一个人结婚了,从此有了对股东和家人的责任,年年花天酒地、入不敷出那是不行的,一个全球占最大份额的全平台游戏引擎股价从200多跌到20多,说明它原先够优秀够廉价,居然不准他为了盈利涨一点点价?何况涨价后还是最便宜的,骂他不跟用户充分沟通,那些大用户也没沟通翻脸不认人破口大骂就有理了?","text":"先讲个故事: 那个人太不像话了,以前每次碰到他都会给5个刀给我,从昨天开始居然说他也要向家人交代,以后每次只能给我2.5刀了!要是有给的更多的人,真不想碰到他了,有吗?居然还是他给的最多![捂脸] $Unity Software Inc.(U)$ 一个公司上市了就像一个人结婚了,从此有了对股东和家人的责任,年年花天酒地、入不敷出那是不行的,一个全球占最大份额的全平台游戏引擎股价从200多跌到20多,说明它原先够优秀够廉价,居然不准他为了盈利涨一点点价?何况涨价后还是最便宜的,骂他不跟用户充分沟通,那些大用户也没沟通翻脸不认人破口大骂就有理了?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/224667246805064","repostId":"1133121639","repostType":2,"isVote":1,"tweetType":1,"viewCount":3219,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":220313271382152,"gmtCreate":1694808729486,"gmtModify":1694808730708,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"Replying to <a href=\"https://laohu8.com/U/3576468087813074\">@苹果拥护者</a>: <a href=\"https://laohu8.com/S/U\"> $Unity Software Inc.(U)$ </a> 通过硬件ID识别,即使你重新安装系统,服务器也能识别是否是重复安装,同理,欺诈性安装更能识别。如果同时记录几个硬件的ID,则即使你换了个别硬件也还能识别,比如硬盘序列号、网络物理序列号、CPU序列号等,这些都具备全球唯一性特征。//<a href=\"https://laohu8.com/U/3576468087813074\">@苹果拥护者</a>:1、所有休闲游戏都会和unity说拜拜 2、欺诈安装你如何识别?如何合作? 3、重复安装不同端口安装你又如何识别?这些都是无法识别的东西","listText":"Replying to <a href=\"https://laohu8.com/U/3576468087813074\">@苹果拥护者</a>: <a href=\"https://laohu8.com/S/U\"> $Unity Software Inc.(U)$ </a> 通过硬件ID识别,即使你重新安装系统,服务器也能识别是否是重复安装,同理,欺诈性安装更能识别。如果同时记录几个硬件的ID,则即使你换了个别硬件也还能识别,比如硬盘序列号、网络物理序列号、CPU序列号等,这些都具备全球唯一性特征。//<a href=\"https://laohu8.com/U/3576468087813074\">@苹果拥护者</a>:1、所有休闲游戏都会和unity说拜拜 2、欺诈安装你如何识别?如何合作? 3、重复安装不同端口安装你又如何识别?这些都是无法识别的东西","text":"Replying to @苹果拥护者: $Unity Software Inc.(U)$ 通过硬件ID识别,即使你重新安装系统,服务器也能识别是否是重复安装,同理,欺诈性安装更能识别。如果同时记录几个硬件的ID,则即使你换了个别硬件也还能识别,比如硬盘序列号、网络物理序列号、CPU序列号等,这些都具备全球唯一性特征。//@苹果拥护者:1、所有休闲游戏都会和unity说拜拜 2、欺诈安装你如何识别?如何合作? 3、重复安装不同端口安装你又如何识别?这些都是无法识别的东西","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/220313271382152","repostId":"219725793951752","repostType":1,"repost":{"id":219725793951752,"gmtCreate":1694680028328,"gmtModify":1694680813609,"author":{"id":"3574917796328560","authorId":"3574917796328560","name":"钛媒体APP","avatar":"https://static.tigerbbs.com/a30e6edce861fd1d3d0c1268a2d83b40","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574917796328560","authorIdStr":"3574917796328560"},"themes":[],"title":"Unity回应:Runtime模式仅针对新安装游戏收取费用,90%以上客户不受影响","htmlText":"钛媒体App获悉,针对实时3D内容创作与运营平台Unity计划收取额外Runtime费用模式争议话题,9月14日下午,Unity公司在向钛媒体App展示的一份澄清回应称: 明年1月1日起的Runtime费用模式仅针对新安装游戏收取费用,需要同时满足安装量和收入两个门槛,而不是持续性支付永久性许可权使用费。 Unity强调,公司90%以上的客户都不会受到这一变化的影响,受影响部分是在游戏下载量、收入规模较大,且符合Unity Runtime费用模式门槛的客户。 据悉,美国时间9月12日,Unity公司宣布了一项调整,称满足相关条件下,从2024年1月1日起开始额外收取“Unity Runtime Fee费用”,该费用将根据游戏安装数量而定(不同订阅服务指标不同),主要原则是基于用户安装游戏的频率以及相关游戏的收入。 Unity Create总裁Marc Whitten表示,Unity此次推出Runtime的核心点,只是确保公司y与开发者之间拥有正确的价值交换,以便更好投资发展引擎技术,并且确保Unity能够为人们提供制作出色游戏软件工具。他强调,Unity正在倾听开发者声音,确保提供最好的服务。 事实上,在此之前,Unity主要依靠薄利多销的包月收费模式获得收入,但该公司的收入低于核心产品价值,而且远低于Adobe、英伟达、高通、Arm等同类型技术、同类商业模式企业。而Unity公司的发展核心,依然是收入来源和游戏规模的高速增长。 (详见钛媒体App前文:《Unity中国:团结引擎9月起内测,AI 技术将渗透游戏开发全过程》) 今年8月Unity(NYSE: U)发布的2023财年第二季度财报显示,营收5.33亿美元,同比增长80%,好于外界预期的5.15亿美元,但同期净亏损为1.93亿美元。相比之下,拥有图像和 AI 引擎技术的英伟达,二季度营收达135.1亿美元","listText":"钛媒体App获悉,针对实时3D内容创作与运营平台Unity计划收取额外Runtime费用模式争议话题,9月14日下午,Unity公司在向钛媒体App展示的一份澄清回应称: 明年1月1日起的Runtime费用模式仅针对新安装游戏收取费用,需要同时满足安装量和收入两个门槛,而不是持续性支付永久性许可权使用费。 Unity强调,公司90%以上的客户都不会受到这一变化的影响,受影响部分是在游戏下载量、收入规模较大,且符合Unity Runtime费用模式门槛的客户。 据悉,美国时间9月12日,Unity公司宣布了一项调整,称满足相关条件下,从2024年1月1日起开始额外收取“Unity Runtime Fee费用”,该费用将根据游戏安装数量而定(不同订阅服务指标不同),主要原则是基于用户安装游戏的频率以及相关游戏的收入。 Unity Create总裁Marc Whitten表示,Unity此次推出Runtime的核心点,只是确保公司y与开发者之间拥有正确的价值交换,以便更好投资发展引擎技术,并且确保Unity能够为人们提供制作出色游戏软件工具。他强调,Unity正在倾听开发者声音,确保提供最好的服务。 事实上,在此之前,Unity主要依靠薄利多销的包月收费模式获得收入,但该公司的收入低于核心产品价值,而且远低于Adobe、英伟达、高通、Arm等同类型技术、同类商业模式企业。而Unity公司的发展核心,依然是收入来源和游戏规模的高速增长。 (详见钛媒体App前文:《Unity中国:团结引擎9月起内测,AI 技术将渗透游戏开发全过程》) 今年8月Unity(NYSE: U)发布的2023财年第二季度财报显示,营收5.33亿美元,同比增长80%,好于外界预期的5.15亿美元,但同期净亏损为1.93亿美元。相比之下,拥有图像和 AI 引擎技术的英伟达,二季度营收达135.1亿美元","text":"钛媒体App获悉,针对实时3D内容创作与运营平台Unity计划收取额外Runtime费用模式争议话题,9月14日下午,Unity公司在向钛媒体App展示的一份澄清回应称: 明年1月1日起的Runtime费用模式仅针对新安装游戏收取费用,需要同时满足安装量和收入两个门槛,而不是持续性支付永久性许可权使用费。 Unity强调,公司90%以上的客户都不会受到这一变化的影响,受影响部分是在游戏下载量、收入规模较大,且符合Unity Runtime费用模式门槛的客户。 据悉,美国时间9月12日,Unity公司宣布了一项调整,称满足相关条件下,从2024年1月1日起开始额外收取“Unity Runtime Fee费用”,该费用将根据游戏安装数量而定(不同订阅服务指标不同),主要原则是基于用户安装游戏的频率以及相关游戏的收入。 Unity Create总裁Marc Whitten表示,Unity此次推出Runtime的核心点,只是确保公司y与开发者之间拥有正确的价值交换,以便更好投资发展引擎技术,并且确保Unity能够为人们提供制作出色游戏软件工具。他强调,Unity正在倾听开发者声音,确保提供最好的服务。 事实上,在此之前,Unity主要依靠薄利多销的包月收费模式获得收入,但该公司的收入低于核心产品价值,而且远低于Adobe、英伟达、高通、Arm等同类型技术、同类商业模式企业。而Unity公司的发展核心,依然是收入来源和游戏规模的高速增长。 (详见钛媒体App前文:《Unity中国:团结引擎9月起内测,AI 技术将渗透游戏开发全过程》) 今年8月Unity(NYSE: U)发布的2023财年第二季度财报显示,营收5.33亿美元,同比增长80%,好于外界预期的5.15亿美元,但同期净亏损为1.93亿美元。相比之下,拥有图像和 AI 引擎技术的英伟达,二季度营收达135.1亿美元","images":[{"img":"https://static.tigerbbs.com/f5ac684d420447d58ab8ee8c76e69a1b"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/219725793951752","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":3491,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3576468087813074","authorId":"3576468087813074","name":"苹果拥护者","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"idStr":"3576468087813074","authorIdStr":"3576468087813074"},"content":"居然是回复我的[开心]。这样给你说吧,我是个用unity的开发者。欺诈性安装是无法识别的,连苹果都无法做到的事,你认为unity可以做到?你说的这些序号都是可以完全伪造的。","text":"居然是回复我的[开心]。这样给你说吧,我是个用unity的开发者。欺诈性安装是无法识别的,连苹果都无法做到的事,你认为unity可以做到?你说的这些序号都是可以完全伪造的。","html":"居然是回复我的[开心]。这样给你说吧,我是个用unity的开发者。欺诈性安装是无法识别的,连苹果都无法做到的事,你认为unity可以做到?你说的这些序号都是可以完全伪造的。"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":207247184244744,"gmtCreate":1691626398584,"gmtModify":1691626400123,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"利用好已经拥有的市场先发优势,抓住今年AI大爆发机会,未来可期!","listText":"利用好已经拥有的市场先发优势,抓住今年AI大爆发机会,未来可期!","text":"利用好已经拥有的市场先发优势,抓住今年AI大爆发机会,未来可期!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/207247184244744","isVote":1,"tweetType":1,"viewCount":2537,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":204759490068728,"gmtCreate":1691021446548,"gmtModify":1691021448228,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"是的,现金收入那么多,净资产每股65美金,居然不分红,不然股价立马翻1-2倍。","listText":"是的,现金收入那么多,净资产每股65美金,居然不分红,不然股价立马翻1-2倍。","text":"是的,现金收入那么多,净资产每股65美金,居然不分红,不然股价立马翻1-2倍。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/204759490068728","repostId":"652521578","repostType":1,"repost":{"id":652521578,"gmtCreate":1684766941294,"gmtModify":1684767824130,"author":{"id":"171831165131674","authorId":"171831165131674","name":"为而不争001","avatar":"https://static.tigerbbs.com/eaabc3dc32cfa8a4b00d43c9fd309645","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"idStr":"171831165131674","authorIdStr":"171831165131674"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/DQ\">$大全新能源(DQ)$ </a>垃圾公司,不分红铁公鸡","listText":"<a href=\"https://laohu8.com/S/DQ\">$大全新能源(DQ)$ </a>垃圾公司,不分红铁公鸡","text":"$大全新能源(DQ)$ 垃圾公司,不分红铁公鸡","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/652521578","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2242,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":197906760507416,"gmtCreate":1689339628090,"gmtModify":1689339629281,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NOK\">$诺基亚(NOK)$ </a>反应有点过激了,预计的业绩也没下多少,几个点而已,只能说借机做空者厉害!","listText":"<a href=\"https://laohu8.com/S/NOK\">$诺基亚(NOK)$ </a>反应有点过激了,预计的业绩也没下多少,几个点而已,只能说借机做空者厉害!","text":"$诺基亚(NOK)$ 反应有点过激了,预计的业绩也没下多少,几个点而已,只能说借机做空者厉害!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/197906760507416","isVote":1,"tweetType":1,"viewCount":49415,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":655111410,"gmtCreate":1688167732830,"gmtModify":1688173733079,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"躲过了美联储的围追堵截,却不小心中了港股的招!","listText":"躲过了美联储的围追堵截,却不小心中了港股的招!","text":"躲过了美联储的围追堵截,却不小心中了港股的招!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/655111410","repostId":"192785499242520","repostType":1,"repost":{"id":192785499242520,"gmtCreate":1688092024277,"gmtModify":1688092067683,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/9e396d03155923b283948d2dec9191f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"36984908995200","authorIdStr":"36984908995200"},"themes":[],"title":"【有奖活动】一句话形容我的2023上半年","htmlText":"疯狂星期五又来了,小虎君又来给大家发福利了,欢迎大家在评论区留言,参与“一句话形容我的2023上半年”活动,在评论区用一句话留下您对2023上半年的精彩总结,即有机会赢取丰厚虎币和神秘惊喜!活动火爆进行中,快来分享您的故事吧【参与方式】在评论区留言!同时转发本贴!在评论区用一句话留下您对2023上半年的精彩总结,并艾特你的朋友来参与活动。(不局限于投票投资,也可以是学习或者生活的总结)⏰活动时间活动持续到7月7日🎁活动奖品凡是在评论区留言的虎友,均可获得10虎币,评论区互动最高的1个虎友以及最幽默的虎友均可获得“神秘惊喜”🎁🎁活动火爆进行中,快来分享您的故事吧🎉 <a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a>如果想多聊聊自己的2023投资总结,也欢迎参与我们的活动 <a href=\"https://laohu8.com/TW/192304188002352\" target=\"_blank\">【2023上半年投资大复盘】如何在“牛市”中实现爆发式增长的?</a>分享投资心得和成功故事,就有机会获得股票代金券、免佣卡以及限量周边!","listText":"疯狂星期五又来了,小虎君又来给大家发福利了,欢迎大家在评论区留言,参与“一句话形容我的2023上半年”活动,在评论区用一句话留下您对2023上半年的精彩总结,即有机会赢取丰厚虎币和神秘惊喜!活动火爆进行中,快来分享您的故事吧【参与方式】在评论区留言!同时转发本贴!在评论区用一句话留下您对2023上半年的精彩总结,并艾特你的朋友来参与活动。(不局限于投票投资,也可以是学习或者生活的总结)⏰活动时间活动持续到7月7日🎁活动奖品凡是在评论区留言的虎友,均可获得10虎币,评论区互动最高的1个虎友以及最幽默的虎友均可获得“神秘惊喜”🎁🎁活动火爆进行中,快来分享您的故事吧🎉 <a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a>如果想多聊聊自己的2023投资总结,也欢迎参与我们的活动 <a href=\"https://laohu8.com/TW/192304188002352\" target=\"_blank\">【2023上半年投资大复盘】如何在“牛市”中实现爆发式增长的?</a>分享投资心得和成功故事,就有机会获得股票代金券、免佣卡以及限量周边!","text":"疯狂星期五又来了,小虎君又来给大家发福利了,欢迎大家在评论区留言,参与“一句话形容我的2023上半年”活动,在评论区用一句话留下您对2023上半年的精彩总结,即有机会赢取丰厚虎币和神秘惊喜!活动火爆进行中,快来分享您的故事吧【参与方式】在评论区留言!同时转发本贴!在评论区用一句话留下您对2023上半年的精彩总结,并艾特你的朋友来参与活动。(不局限于投票投资,也可以是学习或者生活的总结)⏰活动时间活动持续到7月7日🎁活动奖品凡是在评论区留言的虎友,均可获得10虎币,评论区互动最高的1个虎友以及最幽默的虎友均可获得“神秘惊喜”🎁🎁活动火爆进行中,快来分享您的故事吧🎉 $老虎证券(TIGR)$如果想多聊聊自己的2023投资总结,也欢迎参与我们的活动 【2023上半年投资大复盘】如何在“牛市”中实现爆发式增长的?分享投资心得和成功故事,就有机会获得股票代金券、免佣卡以及限量周边!","images":[{"img":"https://static.tigerbbs.com/ca2d25593a99d7958f291dfb3f57fd64","width":"940","height":"788"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/192785499242520","isVote":2,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"vote":{"id":2756,"gmtBegin":1688093361010,"gmtEnd":1688696921423,"type":1,"upper":1,"title":"2023上半年你赚钱了吗?","choices":[{"id":10123,"sort":1,"name":"赚麻了","userSize":29,"voted":false},{"id":10124,"sort":2,"name":"亏惨了","userSize":38,"voted":false},{"id":10125,"sort":3,"name":"不赚不亏","userSize":29,"voted":false}]},"comments":[],"imageCount":2,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":5113,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":446354,"gmtCreate":1553701529180,"gmtModify":1704795292758,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"$宜人贷(YRD)$$老虎证券(TIGR)$ $拍拍贷(PPDF)$ $蝙蝠集团(GLG)$ $和信贷(HX)$ 刚才有朋友问我为什么这几天总是暗推大陆理财股票,简单说几点: 1、弹坑理论,也就是刚刚被炸过的地方最安全,有人想它死的、能力差的、不合规的、运气不好的公司都死了,剩下的就安全了。 2、股价大幅度下降了,而且少了很多很多竞争者,日子反而会更好过。 3、已经有好几家同类公司已经公布业绩,四季度均在明显恢复。 4、经过去年的灾难,这些公司均在置入优良资产或回购股票,而市场需求是基本不变的。 5、综上,难道这些股票还有下跌的理由吗?除非庄家忽悠做空,但目的就是收集筹码。 6、虽然不是百分之百盈利,如果这样的机会如果还不敢冒险,那还炒什么股票呢[可爱]","listText":"$宜人贷(YRD)$$老虎证券(TIGR)$ $拍拍贷(PPDF)$ $蝙蝠集团(GLG)$ $和信贷(HX)$ 刚才有朋友问我为什么这几天总是暗推大陆理财股票,简单说几点: 1、弹坑理论,也就是刚刚被炸过的地方最安全,有人想它死的、能力差的、不合规的、运气不好的公司都死了,剩下的就安全了。 2、股价大幅度下降了,而且少了很多很多竞争者,日子反而会更好过。 3、已经有好几家同类公司已经公布业绩,四季度均在明显恢复。 4、经过去年的灾难,这些公司均在置入优良资产或回购股票,而市场需求是基本不变的。 5、综上,难道这些股票还有下跌的理由吗?除非庄家忽悠做空,但目的就是收集筹码。 6、虽然不是百分之百盈利,如果这样的机会如果还不敢冒险,那还炒什么股票呢[可爱]","text":"$宜人贷(YRD)$$老虎证券(TIGR)$ $拍拍贷(PPDF)$ $蝙蝠集团(GLG)$ $和信贷(HX)$ 刚才有朋友问我为什么这几天总是暗推大陆理财股票,简单说几点: 1、弹坑理论,也就是刚刚被炸过的地方最安全,有人想它死的、能力差的、不合规的、运气不好的公司都死了,剩下的就安全了。 2、股价大幅度下降了,而且少了很多很多竞争者,日子反而会更好过。 3、已经有好几家同类公司已经公布业绩,四季度均在明显恢复。 4、经过去年的灾难,这些公司均在置入优良资产或回购股票,而市场需求是基本不变的。 5、综上,难道这些股票还有下跌的理由吗?除非庄家忽悠做空,但目的就是收集筹码。 6、虽然不是百分之百盈利,如果这样的机会如果还不敢冒险,那还炒什么股票呢[可爱]","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":27,"commentSize":17,"repostSize":1,"link":"https://laohu8.com/post/446354","isVote":1,"tweetType":1,"viewCount":8327,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3506000781942170","authorId":"3506000781942170","name":"大头老李不大头","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"idStr":"3506000781942170","authorIdStr":"3506000781942170"},"content":"实话说我刚炒美股几周,360金融,宜人贷占90%,拍拍贷和信贷10%,都算高位站岗,但我心也不慌,直觉同你一样,只是没有你那么细腻讲的明白,我想留半年后再打开看看,您觉的还有哪些值得博?老虎证卷博傻性质值得短期参于一下么?还是其它什么票?求指教!","text":"实话说我刚炒美股几周,360金融,宜人贷占90%,拍拍贷和信贷10%,都算高位站岗,但我心也不慌,直觉同你一样,只是没有你那么细腻讲的明白,我想留半年后再打开看看,您觉的还有哪些值得博?老虎证卷博傻性质值得短期参于一下么?还是其它什么票?求指教!","html":"实话说我刚炒美股几周,360金融,宜人贷占90%,拍拍贷和信贷10%,都算高位站岗,但我心也不慌,直觉同你一样,只是没有你那么细腻讲的明白,我想留半年后再打开看看,您觉的还有哪些值得博?老虎证卷博傻性质值得短期参于一下么?还是其它什么票?求指教!"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":378921105,"gmtCreate":1618993178707,"gmtModify":1619017359998,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/YQ\">$一起教育科技(YQ)$</a>跌到3-5元,如果天朝小朋友被各种补课残害的现象还没有改观的话,可以抄底做一波,但长线不行,我始终相信天朝的小孩不会这么不幸,快乐的童年必须回归! 我现在最骄傲的就是我的童年,还有我小孩的童年被我引导的都不怎么把学习成绩当一回事,每当考试成绩差一些,我就鼓励:恭喜,又给以后留下了进步的空间! 人生就是百十年,纯真的、无忧无虑的快乐童年是人生最重要的,大部分的人长大后直到老年再也不会有那样的快乐了<a href=\"https://laohu8.com/S/GSX\">$跟谁学(GSX)$</a>","listText":"<a href=\"https://laohu8.com/S/YQ\">$一起教育科技(YQ)$</a>跌到3-5元,如果天朝小朋友被各种补课残害的现象还没有改观的话,可以抄底做一波,但长线不行,我始终相信天朝的小孩不会这么不幸,快乐的童年必须回归! 我现在最骄傲的就是我的童年,还有我小孩的童年被我引导的都不怎么把学习成绩当一回事,每当考试成绩差一些,我就鼓励:恭喜,又给以后留下了进步的空间! 人生就是百十年,纯真的、无忧无虑的快乐童年是人生最重要的,大部分的人长大后直到老年再也不会有那样的快乐了<a href=\"https://laohu8.com/S/GSX\">$跟谁学(GSX)$</a>","text":"$一起教育科技(YQ)$跌到3-5元,如果天朝小朋友被各种补课残害的现象还没有改观的话,可以抄底做一波,但长线不行,我始终相信天朝的小孩不会这么不幸,快乐的童年必须回归! 我现在最骄傲的就是我的童年,还有我小孩的童年被我引导的都不怎么把学习成绩当一回事,每当考试成绩差一些,我就鼓励:恭喜,又给以后留下了进步的空间! 人生就是百十年,纯真的、无忧无虑的快乐童年是人生最重要的,大部分的人长大后直到老年再也不会有那样的快乐了$跟谁学(GSX)$","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":13,"commentSize":16,"repostSize":2,"link":"https://laohu8.com/post/378921105","isVote":1,"tweetType":1,"viewCount":9074,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3548035630775276","authorId":"3548035630775276","name":"Steven S","avatar":"https://static.tigerbbs.com/1ebba660e3b3f9e8b96c282c18a6178e","crmLevel":9,"crmLevelSwitch":1,"idStr":"3548035630775276","authorIdStr":"3548035630775276"},"content":"说了些屁话 童年快不快乐跟补课学习有啥直接联系吗 每天去活泥巴捉泥鳅就是快乐吗 当你看到孩子长大后啥都不会为生计发愁的时候 童年的那些回忆能当饭吃吗 三观正积极乐观的心态才是快乐的根本 你说的那些只是当前压力的借口 对生活压力的逃避罢了","text":"说了些屁话 童年快不快乐跟补课学习有啥直接联系吗 每天去活泥巴捉泥鳅就是快乐吗 当你看到孩子长大后啥都不会为生计发愁的时候 童年的那些回忆能当饭吃吗 三观正积极乐观的心态才是快乐的根本 你说的那些只是当前压力的借口 对生活压力的逃避罢了","html":"说了些屁话 童年快不快乐跟补课学习有啥直接联系吗 每天去活泥巴捉泥鳅就是快乐吗 当你看到孩子长大后啥都不会为生计发愁的时候 童年的那些回忆能当饭吃吗 三观正积极乐观的心态才是快乐的根本 你说的那些只是当前压力的借口 对生活压力的逃避罢了"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":313000703,"gmtCreate":1611630500202,"gmtModify":1703751751797,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/09911\">$赤子城科技(09911)$</a><a href=\"https://laohu8.com/S/YALA\">$Yalla Group(YALA)$</a><a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a> 跟踪赤子城2-3个月了,特破前一天还加了一点货,还是掌握的不错。一直认为赤子城是最合适对标YALA的股票,业务几乎一样,都是游戏加社交,主战场也重叠不少地区,控股的都是国人……,看数据赤子城更胜一筹,而且赤子城前期和最近得好多大奖,总之非常值得期待。 再看股价,一个3元港币,也就0.4美元左右,而yala现价是24-26美金了,要说没有一个巨大的机会,很难让人接受吧? 机构、庄家会放过这样的机会吗? 当然上涨一定是曲折的,各自设定目标吧,yala我是16元左右就跑了,老虎证券也是10元不到就跑了大部分,赤子城看看情况,希望跑迟一点[微笑] ","listText":"<a href=\"https://laohu8.com/S/09911\">$赤子城科技(09911)$</a><a href=\"https://laohu8.com/S/YALA\">$Yalla Group(YALA)$</a><a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a> 跟踪赤子城2-3个月了,特破前一天还加了一点货,还是掌握的不错。一直认为赤子城是最合适对标YALA的股票,业务几乎一样,都是游戏加社交,主战场也重叠不少地区,控股的都是国人……,看数据赤子城更胜一筹,而且赤子城前期和最近得好多大奖,总之非常值得期待。 再看股价,一个3元港币,也就0.4美元左右,而yala现价是24-26美金了,要说没有一个巨大的机会,很难让人接受吧? 机构、庄家会放过这样的机会吗? 当然上涨一定是曲折的,各自设定目标吧,yala我是16元左右就跑了,老虎证券也是10元不到就跑了大部分,赤子城看看情况,希望跑迟一点[微笑] ","text":"$赤子城科技(09911)$$Yalla Group(YALA)$$老虎证券(TIGR)$ 跟踪赤子城2-3个月了,特破前一天还加了一点货,还是掌握的不错。一直认为赤子城是最合适对标YALA的股票,业务几乎一样,都是游戏加社交,主战场也重叠不少地区,控股的都是国人……,看数据赤子城更胜一筹,而且赤子城前期和最近得好多大奖,总之非常值得期待。 再看股价,一个3元港币,也就0.4美元左右,而yala现价是24-26美金了,要说没有一个巨大的机会,很难让人接受吧? 机构、庄家会放过这样的机会吗? 当然上涨一定是曲折的,各自设定目标吧,yala我是16元左右就跑了,老虎证券也是10元不到就跑了大部分,赤子城看看情况,希望跑迟一点[微笑]","images":[],"top":1,"highlighted":1,"essential":2,"paper":1,"likeSize":9,"commentSize":2,"repostSize":2,"link":"https://laohu8.com/post/313000703","isVote":1,"tweetType":1,"viewCount":12332,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3542699457221316","authorId":"3542699457221316","name":"小狼666","avatar":"https://static.tigerbbs.com/82441e1e6d502bf29134c88427988379","crmLevel":1,"crmLevelSwitch":0,"idStr":"3542699457221316","authorIdStr":"3542699457221316"},"content":"这个光比较单价还是不太合适的,还是要看看市盈率和成长性的","text":"这个光比较单价还是不太合适的,还是要看看市盈率和成长性的","html":"这个光比较单价还是不太合适的,还是要看看市盈率和成长性的"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":367316918,"gmtCreate":1614909830734,"gmtModify":1703482840522,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/09911\">$赤子城科技(09911)$</a><a href=\"https://laohu8.com/S/YALA\">$Yalla Group(YALA)$</a>看在赤子城收入增长到去年300%的面子上(19年3.9亿,20年11亿,股价刚好倒过来,11元多跌到3.9元!),尝试少量适当抄底,希望继续下跌空间不大,反正拿得住就行。","listText":"<a href=\"https://laohu8.com/S/09911\">$赤子城科技(09911)$</a><a href=\"https://laohu8.com/S/YALA\">$Yalla Group(YALA)$</a>看在赤子城收入增长到去年300%的面子上(19年3.9亿,20年11亿,股价刚好倒过来,11元多跌到3.9元!),尝试少量适当抄底,希望继续下跌空间不大,反正拿得住就行。","text":"$赤子城科技(09911)$$Yalla Group(YALA)$看在赤子城收入增长到去年300%的面子上(19年3.9亿,20年11亿,股价刚好倒过来,11元多跌到3.9元!),尝试少量适当抄底,希望继续下跌空间不大,反正拿得住就行。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":8,"repostSize":4,"link":"https://laohu8.com/post/367316918","isVote":1,"tweetType":1,"viewCount":5526,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3508369543754029","authorId":"3508369543754029","name":"卧龙老仙","avatar":"https://static.tigerbbs.com/b4bf784c845d4f8189a022d9d008486e","crmLevel":1,"crmLevelSwitch":0,"idStr":"3508369543754029","authorIdStr":"3508369543754029"},"content":"公告明明写着“截至2020年12月31日止,赤子城科技(9911.HK)2020年拥有人应佔利润约人民币33至47百万元,较2019年同期减少约30%至50%”,这个是什么意思啊?","text":"公告明明写着“截至2020年12月31日止,赤子城科技(9911.HK)2020年拥有人应佔利润约人民币33至47百万元,较2019年同期减少约30%至50%”,这个是什么意思啊?","html":"公告明明写着“截至2020年12月31日止,赤子城科技(9911.HK)2020年拥有人应佔利润约人民币33至47百万元,较2019年同期减少约30%至50%”,这个是什么意思啊?"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":970858307,"gmtCreate":1597745227509,"gmtModify":1704216547124,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a>谁有巫总的邮箱、微信等联系方式,我给他几个建议和一个忠告,老虎的问题比较特出,只要抓住重点解决起来也不难,我有9.3层把握让老虎业绩短时间内大幅增长,大幅!股价自然是水涨船高; 忠告是发现老虎有个致命问题,致命!如不尽快解决我都不敢长期持有老虎股票,甚至不敢呆着老虎,要转到其它证券公司。","listText":"<a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a>谁有巫总的邮箱、微信等联系方式,我给他几个建议和一个忠告,老虎的问题比较特出,只要抓住重点解决起来也不难,我有9.3层把握让老虎业绩短时间内大幅增长,大幅!股价自然是水涨船高; 忠告是发现老虎有个致命问题,致命!如不尽快解决我都不敢长期持有老虎股票,甚至不敢呆着老虎,要转到其它证券公司。","text":"$老虎证券(TIGR)$谁有巫总的邮箱、微信等联系方式,我给他几个建议和一个忠告,老虎的问题比较特出,只要抓住重点解决起来也不难,我有9.3层把握让老虎业绩短时间内大幅增长,大幅!股价自然是水涨船高; 忠告是发现老虎有个致命问题,致命!如不尽快解决我都不敢长期持有老虎股票,甚至不敢呆着老虎,要转到其它证券公司。","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":7,"commentSize":13,"repostSize":0,"link":"https://laohu8.com/post/970858307","isVote":1,"tweetType":1,"viewCount":6482,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"content":"只方便口头说说,最重要的事情往往是最简单的事情,不夸张也不危言耸听。","text":"只方便口头说说,最重要的事情往往是最简单的事情,不夸张也不危言耸听。","html":"只方便口头说说,最重要的事情往往是最简单的事情,不夸张也不危言耸听。"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":382694845264256,"gmtCreate":1734466714301,"gmtModify":1734466716222,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/YHC\">$LQR House Inc.(YHC)$ </a> 是不是要被收购了?好像看到有一个12.20的投票截止日的邮件。","listText":"<a href=\"https://laohu8.com/S/YHC\">$LQR House Inc.(YHC)$ </a> 是不是要被收购了?好像看到有一个12.20的投票截止日的邮件。","text":"$LQR House Inc.(YHC)$ 是不是要被收购了?好像看到有一个12.20的投票截止日的邮件。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/382694845264256","isVote":1,"tweetType":1,"viewCount":2427,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":449696198869584,"gmtCreate":1750815605788,"gmtModify":1750815607120,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01171\">$兖矿能源(01171)$ </a> 咨询一下各位朋友,前阵子的分红大约多久可以达到港股通账号?","listText":"<a href=\"https://laohu8.com/S/01171\">$兖矿能源(01171)$ </a> 咨询一下各位朋友,前阵子的分红大约多久可以达到港股通账号?","text":"$兖矿能源(01171)$ 咨询一下各位朋友,前阵子的分红大约多久可以达到港股通账号?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/449696198869584","isVote":1,"tweetType":1,"viewCount":107,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":908025041,"gmtCreate":1558004501183,"gmtModify":1704803688135,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"$蝙蝠集团(GLG)$ $九洲大药房(CJJD)$$老虎证券(TIGR)$ $小赢科技(XYF)$ 第二轮进入这些经过大跌调整,业绩有保障的股票,尤其是蝙蝠和大药房还有新投资机构按现在股价大约三倍的价钱在大跌前购买大量股票,另外鉴于通讯4G、5G机房设备HW被美国切断关键配件供应链,预计$诺基亚(NOK)$ 少了一个最大的竞争对手,下半年开始业绩会大幅好转,提前介入。","listText":"$蝙蝠集团(GLG)$ $九洲大药房(CJJD)$$老虎证券(TIGR)$ $小赢科技(XYF)$ 第二轮进入这些经过大跌调整,业绩有保障的股票,尤其是蝙蝠和大药房还有新投资机构按现在股价大约三倍的价钱在大跌前购买大量股票,另外鉴于通讯4G、5G机房设备HW被美国切断关键配件供应链,预计$诺基亚(NOK)$ 少了一个最大的竞争对手,下半年开始业绩会大幅好转,提前介入。","text":"$蝙蝠集团(GLG)$ $九洲大药房(CJJD)$$老虎证券(TIGR)$ $小赢科技(XYF)$ 第二轮进入这些经过大跌调整,业绩有保障的股票,尤其是蝙蝠和大药房还有新投资机构按现在股价大约三倍的价钱在大跌前购买大量股票,另外鉴于通讯4G、5G机房设备HW被美国切断关键配件供应链,预计$诺基亚(NOK)$ 少了一个最大的竞争对手,下半年开始业绩会大幅好转,提前介入。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":9,"repostSize":0,"link":"https://laohu8.com/post/908025041","isVote":1,"tweetType":1,"viewCount":12040,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3516318046156396","authorId":"3516318046156396","name":"老猫来了","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"idStr":"3516318046156396","authorIdStr":"3516318046156396"},"content":"不熟悉不买","text":"不熟悉不买","html":"不熟悉不买"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":316110911,"gmtCreate":1611921242233,"gmtModify":1703756266900,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GME\">$游戏驿站(GME)$</a><a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a><a href=\"https://laohu8.com/S/AMC\">$AMC院线(AMC)$</a>空头的悲哀在于他要出局之前还必须要变成“多头”买回自己做空的股票,不管有多贵都要认,今天到期的大幅盈利的call单那么多,那些卖出call单的做空者该有多惨啊!","listText":"<a href=\"https://laohu8.com/S/GME\">$游戏驿站(GME)$</a><a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a><a href=\"https://laohu8.com/S/AMC\">$AMC院线(AMC)$</a>空头的悲哀在于他要出局之前还必须要变成“多头”买回自己做空的股票,不管有多贵都要认,今天到期的大幅盈利的call单那么多,那些卖出call单的做空者该有多惨啊!","text":"$游戏驿站(GME)$$老虎证券(TIGR)$$AMC院线(AMC)$空头的悲哀在于他要出局之前还必须要变成“多头”买回自己做空的股票,不管有多贵都要认,今天到期的大幅盈利的call单那么多,那些卖出call单的做空者该有多惨啊!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":13,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/316110911","isVote":1,"tweetType":1,"viewCount":4312,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":449609,"gmtCreate":1553872324945,"gmtModify":1704795702465,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"$宜人贷(YRD)$ $拍拍贷(PPDF)$ $和信贷(HX)$ $蝙蝠集团(GLG)$ 看到不少反应公司服务质量问题的,把这里当315平台呀,醉翁之意不在酒吧?问过老虎吗?yrd财经网有论坛; baidu也有贴吧,去那里影响大一些。股友何必为难股友呢,攒点钱不容易呀[微笑] 我的结论是公司问题肯定不少,但上涨的潜力更大!","listText":"$宜人贷(YRD)$ $拍拍贷(PPDF)$ $和信贷(HX)$ $蝙蝠集团(GLG)$ 看到不少反应公司服务质量问题的,把这里当315平台呀,醉翁之意不在酒吧?问过老虎吗?yrd财经网有论坛; baidu也有贴吧,去那里影响大一些。股友何必为难股友呢,攒点钱不容易呀[微笑] 我的结论是公司问题肯定不少,但上涨的潜力更大!","text":"$宜人贷(YRD)$ $拍拍贷(PPDF)$ $和信贷(HX)$ $蝙蝠集团(GLG)$ 看到不少反应公司服务质量问题的,把这里当315平台呀,醉翁之意不在酒吧?问过老虎吗?yrd财经网有论坛; baidu也有贴吧,去那里影响大一些。股友何必为难股友呢,攒点钱不容易呀[微笑] 我的结论是公司问题肯定不少,但上涨的潜力更大!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":15,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/449609","isVote":1,"tweetType":1,"viewCount":1380,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3498604367776814","authorId":"3498604367776814","name":"小股神一枚","avatar":"https://static.tigerbbs.com/47ac1c7e059dc7af52698eb5e02bbddb","crmLevel":2,"crmLevelSwitch":0,"idStr":"3498604367776814","authorIdStr":"3498604367776814"},"content":"我也发现了、股票涨一点就有人上来喷!我们这是炒股的地方……别一天天瞎折腾","text":"我也发现了、股票涨一点就有人上来喷!我们这是炒股的地方……别一天天瞎折腾","html":"我也发现了、股票涨一点就有人上来喷!我们这是炒股的地方……别一天天瞎折腾"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":856384324,"gmtCreate":1635151412955,"gmtModify":1635152108760,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PHUN\">$Phunware, Inc.(PHUN)$</a>等APP上线后,这个股票市值绝对超过50亿美金,川普真相社交平台的技术都是 $Phunware, Inc.(PHUN)$ 来运作,业务稳当,前景不可限量,或者被真相社交平台溢价收购也是可能的。","listText":"<a href=\"https://laohu8.com/S/PHUN\">$Phunware, Inc.(PHUN)$</a>等APP上线后,这个股票市值绝对超过50亿美金,川普真相社交平台的技术都是 $Phunware, Inc.(PHUN)$ 来运作,业务稳当,前景不可限量,或者被真相社交平台溢价收购也是可能的。","text":"$Phunware, Inc.(PHUN)$等APP上线后,这个股票市值绝对超过50亿美金,川普真相社交平台的技术都是 $Phunware, Inc.(PHUN)$ 来运作,业务稳当,前景不可限量,或者被真相社交平台溢价收购也是可能的。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":6,"repostSize":1,"link":"https://laohu8.com/post/856384324","isVote":1,"tweetType":1,"viewCount":4816,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"11965178738539","authorId":"11965178738539","name":"跌跌跌888","avatar":"https://static.tigerbbs.com/b29056b74f08abbc89687e10a0bf2f02","crmLevel":1,"crmLevelSwitch":0,"idStr":"11965178738539","authorIdStr":"11965178738539"},"content":"谁说的是这家公司做的技术?","text":"谁说的是这家公司做的技术?","html":"谁说的是这家公司做的技术?"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":314730784,"gmtCreate":1612371764148,"gmtModify":1703761107976,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ONTX\">$Onconova Therapeutics, Inc.(ONTX)$</a><a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a><a href=\"https://laohu8.com/S/YALA\">$Yalla Group(YALA)$</a>癌症新药出来,不要求涨回原价5000元,小盘股涨回400美元就行。","listText":"<a href=\"https://laohu8.com/S/ONTX\">$Onconova Therapeutics, Inc.(ONTX)$</a><a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a><a href=\"https://laohu8.com/S/YALA\">$Yalla Group(YALA)$</a>癌症新药出来,不要求涨回原价5000元,小盘股涨回400美元就行。","text":"$Onconova Therapeutics, Inc.(ONTX)$$老虎证券(TIGR)$$Yalla Group(YALA)$癌症新药出来,不要求涨回原价5000元,小盘股涨回400美元就行。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":6,"repostSize":1,"link":"https://laohu8.com/post/314730784","isVote":1,"tweetType":1,"viewCount":7733,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3565008982518934","authorId":"3565008982518934","name":"蔡小虎","avatar":"https://static.tigerbbs.com/17cd8f7d28cf053c7d51a9cdc2aeb9a6","crmLevel":2,"crmLevelSwitch":0,"idStr":"3565008982518934","authorIdStr":"3565008982518934"},"content":"为什么说涨回原价5000元,上市不是15元吗?","text":"为什么说涨回原价5000元,上市不是15元吗?","html":"为什么说涨回原价5000元,上市不是15元吗?"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":618853467,"gmtCreate":1650974119092,"gmtModify":1650974119092,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AGMH\">$安高盟(AGMH)$</a>转亏为赢,而且0.17的收益算很不错了,期待进一步表现。","listText":"<a href=\"https://laohu8.com/S/AGMH\">$安高盟(AGMH)$</a>转亏为赢,而且0.17的收益算很不错了,期待进一步表现。","text":"$安高盟(AGMH)$转亏为赢,而且0.17的收益算很不错了,期待进一步表现。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/618853467","isVote":1,"tweetType":1,"viewCount":2846,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":466514,"gmtCreate":1555028091424,"gmtModify":1704797865708,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"$蝙蝠集团(GLG)$ $宜人贷(YRD)$ $拍拍贷(PPDF)$ 蝙蝠这个股票居然可以从涨97%到跌13%,换手率差不多1000%,看来天朝散客不少,从走势来开,3.2左右一刀切下来的行为应该是某个狠庄的行为,看好的朋友可以做T,以后绝对还有机会! 昨天本来打算部分做T,但看到涨的太厉害,从2.8-3.9范围分步全出了,不过后来补仓早了一点,2.6多就开始分布补仓了,现在成本2元,跟原来成本差不多,依然看好蝙蝠价值,记住所谓价值,是可以从很多方面评估的。 宜人贷和啪啪也减仓一部分。","listText":"$蝙蝠集团(GLG)$ $宜人贷(YRD)$ $拍拍贷(PPDF)$ 蝙蝠这个股票居然可以从涨97%到跌13%,换手率差不多1000%,看来天朝散客不少,从走势来开,3.2左右一刀切下来的行为应该是某个狠庄的行为,看好的朋友可以做T,以后绝对还有机会! 昨天本来打算部分做T,但看到涨的太厉害,从2.8-3.9范围分步全出了,不过后来补仓早了一点,2.6多就开始分布补仓了,现在成本2元,跟原来成本差不多,依然看好蝙蝠价值,记住所谓价值,是可以从很多方面评估的。 宜人贷和啪啪也减仓一部分。","text":"$蝙蝠集团(GLG)$ $宜人贷(YRD)$ $拍拍贷(PPDF)$ 蝙蝠这个股票居然可以从涨97%到跌13%,换手率差不多1000%,看来天朝散客不少,从走势来开,3.2左右一刀切下来的行为应该是某个狠庄的行为,看好的朋友可以做T,以后绝对还有机会! 昨天本来打算部分做T,但看到涨的太厉害,从2.8-3.9范围分步全出了,不过后来补仓早了一点,2.6多就开始分布补仓了,现在成本2元,跟原来成本差不多,依然看好蝙蝠价值,记住所谓价值,是可以从很多方面评估的。 宜人贷和啪啪也减仓一部分。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":7,"repostSize":0,"link":"https://laohu8.com/post/466514","isVote":1,"tweetType":1,"viewCount":9519,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3500927620622193","authorId":"3500927620622193","name":"千鸟","avatar":"https://static.tigerbbs.com/7c68f1b5e2239525959b1edc86ca9b5e","crmLevel":1,"crmLevelSwitch":0,"idStr":"3500927620622193","authorIdStr":"3500927620622193"},"content":"短期远离为妙","text":"短期远离为妙","html":"短期远离为妙"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":147836599,"gmtCreate":1626348527811,"gmtModify":1626348527811,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BTBT\">$Bit Digital,Inc(BTBT)$</a><a href=\"https://laohu8.com/S/NCTY\">$第九城市(NCTY)$</a>虽然比特币从5万多价格下跌了30-40%,fil也跌了不少,但比特币挖矿难度也下降了近30%,看好二季度业绩,即使继续跌也预计离底部不远,大陆最不利的消息应该基本上出了,以后反弹高度必须远远超过现价,所以坚持逐步建仓,保守一点先少量建……","listText":"<a href=\"https://laohu8.com/S/BTBT\">$Bit Digital,Inc(BTBT)$</a><a href=\"https://laohu8.com/S/NCTY\">$第九城市(NCTY)$</a>虽然比特币从5万多价格下跌了30-40%,fil也跌了不少,但比特币挖矿难度也下降了近30%,看好二季度业绩,即使继续跌也预计离底部不远,大陆最不利的消息应该基本上出了,以后反弹高度必须远远超过现价,所以坚持逐步建仓,保守一点先少量建……","text":"$Bit Digital,Inc(BTBT)$$第九城市(NCTY)$虽然比特币从5万多价格下跌了30-40%,fil也跌了不少,但比特币挖矿难度也下降了近30%,看好二季度业绩,即使继续跌也预计离底部不远,大陆最不利的消息应该基本上出了,以后反弹高度必须远远超过现价,所以坚持逐步建仓,保守一点先少量建……","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":1,"link":"https://laohu8.com/post/147836599","isVote":1,"tweetType":1,"viewCount":8289,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3587010301156504","authorId":"3587010301156504","name":"Hzlsf","avatar":"https://static.tigerbbs.com/cf79d10ece69deb1be72654e18969250","crmLevel":2,"crmLevelSwitch":0,"idStr":"3587010301156504","authorIdStr":"3587010301156504"},"content":"老千股没有底的","text":"老千股没有底的","html":"老千股没有底的"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":912779733,"gmtCreate":1580476704322,"gmtModify":1704341664740,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FINV\">$信也科技(FINV)$</a> <a href=\"https://laohu8.com/S/XYF\">$小赢科技(XYF)$</a> <a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a> <a href=\"https://laohu8.com/S/HX\">$和信贷(HX)$</a><a href=\"https://laohu8.com/S/YRD\">$宜人贷(YRD)$</a> 做股票要学会观察,国内科技互金有明显放松迹象,北京电视台初一春晚就是由科技互金公司全程赞助,还置入理财节目多个(有心人可以回看),这是近三年来首次出现的,上一次还是16年春节后CCTV的天气预报置入的汇中理财广告,看来整顿已经告一段落,留下的应该基本都是没问题了,而且少了几千个竞争对手机会来了。 虽然近期的武汉肺炎会有短期影响,不过或许可以捡到更便宜的货,反正多种股票逢低分次建仓必有不错的回报。","listText":"<a href=\"https://laohu8.com/S/FINV\">$信也科技(FINV)$</a> <a href=\"https://laohu8.com/S/XYF\">$小赢科技(XYF)$</a> <a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a> <a href=\"https://laohu8.com/S/HX\">$和信贷(HX)$</a><a href=\"https://laohu8.com/S/YRD\">$宜人贷(YRD)$</a> 做股票要学会观察,国内科技互金有明显放松迹象,北京电视台初一春晚就是由科技互金公司全程赞助,还置入理财节目多个(有心人可以回看),这是近三年来首次出现的,上一次还是16年春节后CCTV的天气预报置入的汇中理财广告,看来整顿已经告一段落,留下的应该基本都是没问题了,而且少了几千个竞争对手机会来了。 虽然近期的武汉肺炎会有短期影响,不过或许可以捡到更便宜的货,反正多种股票逢低分次建仓必有不错的回报。","text":"$信也科技(FINV)$ $小赢科技(XYF)$ $老虎证券(TIGR)$ $和信贷(HX)$$宜人贷(YRD)$ 做股票要学会观察,国内科技互金有明显放松迹象,北京电视台初一春晚就是由科技互金公司全程赞助,还置入理财节目多个(有心人可以回看),这是近三年来首次出现的,上一次还是16年春节后CCTV的天气预报置入的汇中理财广告,看来整顿已经告一段落,留下的应该基本都是没问题了,而且少了几千个竞争对手机会来了。 虽然近期的武汉肺炎会有短期影响,不过或许可以捡到更便宜的货,反正多种股票逢低分次建仓必有不错的回报。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/912779733","isVote":1,"tweetType":1,"viewCount":16954,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3539682807868261","authorId":"3539682807868261","name":"小鸟游美股","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"idStr":"3539682807868261","authorIdStr":"3539682807868261"},"content":"换脸才能续命","text":"换脸才能续命","html":"换脸才能续命"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":991236688,"gmtCreate":1564761341444,"gmtModify":1704707834328,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a> 4.01下手补仓,辛辛苦苦做美股赚了的钱都被老虎证券赔回去了,再不争气,只能说明没缘分,只能离开老虎了。","listText":"<a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a> 4.01下手补仓,辛辛苦苦做美股赚了的钱都被老虎证券赔回去了,再不争气,只能说明没缘分,只能离开老虎了。","text":"$老虎证券(TIGR)$ 4.01下手补仓,辛辛苦苦做美股赚了的钱都被老虎证券赔回去了,再不争气,只能说明没缘分,只能离开老虎了。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/991236688","isVote":1,"tweetType":1,"viewCount":2379,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3478234019573091","authorId":"3478234019573091","name":"诸葛长风","avatar":"https://static.tigerbbs.com/584cf6f8ebdb0236f3440d305ea4effc","crmLevel":2,"crmLevelSwitch":0,"idStr":"3478234019573091","authorIdStr":"3478234019573091"},"content":"不可补仓,下跌趋势未完成,此时补过早,会越套越深的","text":"不可补仓,下跌趋势未完成,此时补过早,会越套越深的","html":"不可补仓,下跌趋势未完成,此时补过早,会越套越深的"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":444737,"gmtCreate":1553619296772,"gmtModify":1704795077813,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"$宜人贷(YRD)$为什么我发帖显示成功,却看不到? 其他股票发的贴立马可以看到,只是说到yrd最大利好是宜信做的最好的宜信财富板块置入。不给说吗?","listText":"$宜人贷(YRD)$为什么我发帖显示成功,却看不到? 其他股票发的贴立马可以看到,只是说到yrd最大利好是宜信做的最好的宜信财富板块置入。不给说吗?","text":"$宜人贷(YRD)$为什么我发帖显示成功,却看不到? 其他股票发的贴立马可以看到,只是说到yrd最大利好是宜信做的最好的宜信财富板块置入。不给说吗?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":8,"repostSize":0,"link":"https://laohu8.com/post/444737","isVote":1,"tweetType":1,"viewCount":1149,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3433967817204325","authorId":"3433967817204325","name":"宜人贷庄","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"idStr":"3433967817204325","authorIdStr":"3433967817204325"},"content":"宜信财富根本不参与,老哥","text":"宜信财富根本不参与,老哥","html":"宜信财富根本不参与,老哥"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":624301930,"gmtCreate":1677057207720,"gmtModify":1677057209911,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/U\">$Unity Software Inc.(U)$ </a>关于这个股票,我的观点是,不管目前业绩如何,都要留一点在手上,以防脱手而去,这是一个永远不会饱和的行业,对于大平台的2D、3D游戏、电影电视的特技、元宇宙,U都是最优秀的引擎,而不是最优秀之一。如果仅仅是要体现一些利润出来,其实减少一点创新投入就行。","listText":"<a href=\"https://laohu8.com/S/U\">$Unity Software Inc.(U)$ </a>关于这个股票,我的观点是,不管目前业绩如何,都要留一点在手上,以防脱手而去,这是一个永远不会饱和的行业,对于大平台的2D、3D游戏、电影电视的特技、元宇宙,U都是最优秀的引擎,而不是最优秀之一。如果仅仅是要体现一些利润出来,其实减少一点创新投入就行。","text":"$Unity Software Inc.(U)$ 关于这个股票,我的观点是,不管目前业绩如何,都要留一点在手上,以防脱手而去,这是一个永远不会饱和的行业,对于大平台的2D、3D游戏、电影电视的特技、元宇宙,U都是最优秀的引擎,而不是最优秀之一。如果仅仅是要体现一些利润出来,其实减少一点创新投入就行。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/624301930","isVote":1,"tweetType":1,"viewCount":9543,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3562148271530289","authorId":"3562148271530289","name":"夜流沙","avatar":"https://static.tigerbbs.com/c9cdbfdfad31ab544ec1be7d1f1567e8","crmLevel":3,"crmLevelSwitch":0,"idStr":"3562148271530289","authorIdStr":"3562148271530289"},"content":"同感,感觉随时可能被各个大厂私有化[贱笑]","text":"同感,感觉随时可能被各个大厂私有化[贱笑]","html":"同感,感觉随时可能被各个大厂私有化[贱笑]"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":856312450,"gmtCreate":1635150401299,"gmtModify":1635151290017,"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PHUN\">$Phunware, Inc.(PHUN)$</a>相信川普的号召力! ","listText":"<a href=\"https://laohu8.com/S/PHUN\">$Phunware, Inc.(PHUN)$</a>相信川普的号召力! ","text":"$Phunware, Inc.(PHUN)$相信川普的号召力!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":1,"link":"https://laohu8.com/post/856312450","isVote":1,"tweetType":1,"viewCount":1887,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3493163577009875","authorId":"3493163577009875","name":"飞哥非哥","avatar":"https://static.tigerbbs.com/be30ffbb0d97fa29b176343faa31b553","crmLevel":5,"crmLevelSwitch":1,"idStr":"3493163577009875","authorIdStr":"3493163577009875"},"content":"这一家除了给川普“真相社交“平台设计和运行APP,可能合并之外,还有一个利好,公司第三和第三季度,本身的业绩也是特别好的。","text":"这一家除了给川普“真相社交“平台设计和运行APP,可能合并之外,还有一个利好,公司第三和第三季度,本身的业绩也是特别好的。","html":"这一家除了给川普“真相社交“平台设计和运行APP,可能合并之外,还有一个利好,公司第三和第三季度,本身的业绩也是特别好的。"}],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}